HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

A

UTILITY PATENT APPLICATION TRANSMITTAL *(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))*	Attorney Docket No.	1290.1019-013
	First Named Inventor or Application Identifier	Man Sung Co
	Express Mail Label No.	EL551543910US
Title of Invention	Humanized Immunoglobulin Reactive with B7-2 and Methods of Treatment Therewith	

APPLICATION ELEMENTS	ADDRESS TO:
See MPEP chapter 600 concerning utility patent application contents.	**Assistant Commissioner for Patents** **Box Patent Application** **Washington, D.C. 20231**

1. [X] Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. [X] Specification **[Total Pages [56]]**
(preferred arrangement set forth below)
   - Descriptive title of the invention
   - Cross References to Related Applications
   - Statement Regarding Fed sponsored R & D
   - Reference to microfiche Appendix
   - Background of the Invention
   - Summary of the Invention
   - Brief Description of the Drawings
   - Detailed Description
   - Claim(s)
   - Abstract of the Disclosure

3. [X] Drawing(s) (35 U.S.C. 113) **[Total Sheets [12]]**
   [ ] Formal   [X] Informal

4. [X] Oath or Declaration/POA **[Total Pages [10]]**

   a. [ ] Newly executed (original or copy)

   b. [X] Copy from a prior application (37 C.F.R. 1.63(d))
   (for continuation/divisional with Box 17 completed)
   [NOTE Box 5 below]

      i. [ ] <u>DELETION OF INVENTOR(S)</u>
      Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. [X] Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. [ ] Microfiche Computer Program *(Appendix)*

7. [X] Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

   a. [ ] Computer Readable Copy

   b. [X] Paper Copy (identical to computer copy)
   [10] Pages

   c. [X] Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. [ ] Assignment Papers (cover sheet & documents)

9. [ ] 37 C.F.R. 3.73(b) Statement   [ ] Power of Attorney
(when there is an assignee)

10. [ ] English Translation Document *(if applicable)*

11. [X] Information Disclosure Statement (IDS)/PTO-1449   [ ] Copies of IDS Citations

12. [ ] Preliminary Amendment

13. [X] Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. [ ] Small Entity Statement(s)   [ ] Statement filed in prior application, status still proper and desired

15. [ ] Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. [X] Other: <u>Remarks and Request Under 37 C.F.R. §1.821(e)</u>

---

17. **If a CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

[ ] Continuation   [X] Divisional   [ ] Continuation-in-part (CIP)   of prior application No.:   09/249,011

Prior application information: Examiner: P. Gambel   Group Art Unit: 1644

---

18. CORRESPONDENCE ADDRESS

NAME	Anne J. Collins				
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	Two Militia Drive				
CITY	Lexington	STATE	MA	ZIP CODE	02421-4799
COUNTRY	USA	TELEPHONE	(781) 861-6240	FAX	(781) 861-9540

Signature	*Anne J. Collins*	Date	July 27, 2000
Submitted by Typed or Printed Name	Anne J. Collins	Reg. Number	40,564

Rev. September 23, 1999   ODMA\MHODMA\iManage,150564,1

Date: 7/27/00   Express Mail Label No. EL 55154 3910 US

Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno,
                        Abbie Cheryl Celniker, Mary Collins, Samuel Goldman,
                        Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup
                        and Geertruida Veldman

Attorney's Docket No.:   1290.1019-013

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT THEREWITH

RELATED APPLICATION(S)

This application is a divisional of U.S. Application No. 09/249,011 filed

5   February 12, 1999, the entire teachings of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Antigen specific T-cell activation and the initiation of an immune response

depend initially on the interaction of the T-cell receptor (TCR) complex with the

peptide/major histocompatibility complex (MHC) present on antigen presenting cells

10   (APC). B7 molecules, B7-1 and B7-2, are molecules which are present on APCs. A

second "costimulatory" signal, provided by the interaction of B7-1 and B7-2 on the APC

with their ligands CD28 and CTLA4 on T-cells, is required to complete T-cell

activation and the subsequent regulation of an immune response. A need exists to

regulate the B7-1 and B7-2 pathway, referred to as the B7:cD28/CTLA4 pathway. A

15   further need exists to develop treatments for diseases that are affected by this pathway.

SUMMARY OF THE INVENTION

The invention relates to a humanized immunoglobulin having binding specificity for B7-2, wherein the immunoglobulin comprises an antigen binding region of nonhuman origin (e.g. rodent) and at least a portion of human origin (e.g. a human
5   constant region such as an IgG constant region, a human framework region). In one embodiment, the human constant region can also contain a mutation that reduces the effector function of the humanized immunoglobulin. In another embodiment, the humanized immunoglobulin, described herein, can compete with murine 3D1 for binding to B7-2. In a particular embodiment, the antigen binding region of the
10   humanized immunoglobulin is derived from the 3D1 monoclonal antibody.

The humanized immunoglobulin having binding specificity for B7-2 can comprise a constant region of human origin and an antigen binding region, wherein the antigen binding region of nonhuman origin comprises one or more complementarity determining regions (CDRs) of rodent origin (e.g., derived from 3D1 monoclonal
15   antibody) that binds to B7-2, and the portion of an immunoglobulin of human origin is derived from a human framework region (FR). The antigen binding region can further comprise a light chain and a heavy chain, wherein the light and heavy chain each have three CDRs derived from the 3D1 antibody. The FR of the light chain can be derived, for example, from the light chain of the human H2F antibody and the heavy chain can
20   be derived, for example, from the heavy chain of the human I2R antibody. In a particular embodiment, the invention is a humanized immunoglobulin having binding specificity for B7-2 that is derived from the cell line deposited with the American Type Culture Collection (A.T.C.C.), Accession No. CRL-12524.

The invention also embodies a humanized immunoglobulin having a binding
25   specificity for B7-2 comprising a heavy chain and/or a light chain. The light chain comprises a CDR (e.g., CDR1, CDR2 and CDR3) derived from an antibody of nonhuman origin which binds B7-2 and a FR derived from a light chain of human origin (e.g., H2F antibody). The heavy chain comprises a CDR (e.g.,CDR1, CDR2 and CDR3) derived from an antibody of nonhuman origin which binds B7-2 and a FR region

derived from a heavy chain of human origin (e.g., the human I2R antibody). The immunoglobulin can further comprise CDR1, CDR2 and CDR3 for the light or heavy chain having the amino acid sequence set forth herein or an amino acid substantially the same as the amino acid sequence such that the antibody specifically binds to the B7-2.

5   The present invention also relates to humanized immunoglobulin light chains and to humanized immunoglobulin heavy chains. The invention further relates to isolated nucleic acids comprising a sequence which encodes a humanized immunoglobulin of the present invention (e.g., a single chain antibody), and the invention also relates to isolated nucleic acids that comprise a sequence which encodes a humanized

10   immunoglobulin light chain or heavy chain.

     One embodiment of the invention is a humanized immunoglobulin light chain having binding specificity for B7-2 comprising CDR1, CDR2 and/or CDR3 of the light chain of murine 3D1 antibody, and a human light chain FR (e.g., H2F antibody). Another embodiment is a humanized immunoglobulin light chain that comprises a

15   variable region shown in Figure 2B (SEQ ID NO: 8). The invention also relates to an isolated nucleic acid sequence that encodes a humanized variable light chain specific for B7-2 that comprises a nucleic acid, such as the sequence shown in Figure 2B (SEQ ID NO: 7), a nucleic acid that encodes the amino acid sequence shown in Figure 2B (SEQ ID NO: 8), a nucleic acid which hybridizes thereto under stringent hybridization

20   conditions, and a nucleic acid which is the complement thereof.

     Another embodiment of the invention is a humanized immunoglobulin heavy chain that is specific for B7-2 and comprises CDR1, CDR2 and/or CDR3 of the heavy chain of the 3D1 antibody, and a human heavy chain FR (e.g., I2R antibody). The invention pertains to a humanized immunoglobulin heavy chain that comprises a

25   variable region shown in Figure 2A (SEQ ID NO: 6). The invention also pertains to an isolated nucleic acid sequence that encodes a humanized variable heavy chain specific for B7-2 that comprises a nucleic acid, such as the sequence shown in Figure 2A (SEQ ID NO: 5), a nucleic acid that encodes the amino acid sequence shown in Figure 2A

(SEQ ID NO: 6), a nucleic acid which hybridizes thereto under stringent hybridization conditions, and a nucleic acid which is the complement thereof.

In particular, an embodiment of the invention is a humanized immunoglobulin which specifically binds to B7-2 and comprises a humanized light chain comprising three light chain CDRs from the mouse 3D1 antibody and a light chain variable region framework sequence from a human immunoglobulin light chain, and a humanized heavy chain comprising three heavy chain CDRs from the mouse 3D1 antibody and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain. The mouse 3D1 antibody can further have a mature light chain variable domain, such as the mature light chain variable domain shown in Figure 1B (SEQ ID NO.: 4) and a mature heavy chain variable domain such as the mature heavy chain variable region shown in Figure 1A (SEQ ID NO.: 2).

The invention includes an expression vector that comprises a fused gene which encodes a humanized immunoglobulin light and/or heavy chain. The gene comprises a nucleotide sequence encoding a CDR derived from a light and/or heavy chain of a nonhuman antibody having binding specificity for B7-2 (e.g., murine 3D1 antibody) and a FR derived from a light and/or heavy chain of human origin.

The present invention also relates to a host cell comprising a nucleic acid of the present invention, including one or more constructs comprising nucleic acid of the present invention. In one embodiment, the invention encompasses a host cell comprising a first recombinant nucleic acid that encodes a humanized immunoglobulin light chain and a second recombinant nucleic acid that encodes a humanized immunoglobulin heavy chain. The first nucleic acid comprises a nucleotide sequence encoding a CDR derived from the light chain of murine 3D1 antibody and a FR derived from a light chain of human origin. The second nucleic acid comprises a nucleotide sequence encoding a CDR derived from the heavy chain of murine 3D1 antibody and a FR derived from a heavy chain of human origin. The invention further relates to a host cell comprising a vector or a nucleic acid that encodes the humanized immunoglobulin, as described herein.

The invention further pertains to methods of preparing a humanized immunoglobulin that comprise maintaining a host cell that encodes a humanized immunoglobulin that is specific for B7-2, as described herein, under conditions appropriate for expression of a humanized immunoglobulin, wherein a humanized immunoglobulin chain (one or more) are expressed and a humanized immunoglobulin is produced. The method further comprises the step of isolating the humanized immunoglobulin.

Additional methods encompassed by the invention include a method of inhibiting the interaction of a first cell bearing a B7-2 receptor with a second cell bearing B7-2, comprising contacting the second cell with an effective amount of a humanized immunoglobulin, as described herein. Accordingly, the invention relates to various methods of treatment. The invention includes a method for modulating an immune response of a patient or treating a patient having a transplanted organ, tissue, cell or the like comprising administering an effective amount of the humanized immunoglobulin, as described herein, in a carrier (e.g., pharmaceutical carrier), wherein the immune response is modulated. The invention pertains to treating acute and/or chronic transplant rejection for a prolonged periods of time (e.g., days, months, years). The invention also pertain to methods of treating a disease associated with modulation of the B7-2 molecule (e.g., autoimmune diseases, infectious diseases, inflammatory disorders, systemic lupus erythematosus, diabetes mellitus, insulitis, arthritis, inflammatory bowel disease, inflammatory dermatitis, and multiple sclerosis), comprising administering to a patient an effective amount (e.g., a therapeutically effective amount) of a humanized immunoglobulin, as described herein, in a carrier. Accordingly, the invention encompasses a pharmaceutical composition comprising the humanized antibody, as described herein.

The invention also embodies a method of making a humanized immunoglobulin specific to B7-2 from a murine antibody specific to B7-2. The method comprises determining the CDRs of an antibody of non-human origin (e.g., murine origin) which has binding specificity for B7-2; obtaining a human antibody having a framework

region amino acid sequence suitable for grafting of the CDRs, and grafting the CDRs of an antibody of non-human origin into the FR of the human antibody.

The invention also relates to a method for determining the presence or absence of B7-2 in a sample. The method comprises obtaining the sample to be tested, contacting the sample with a humanized antibody specific to B7-2, or a fragment thereof, sufficiently to allow formation of a complex between B7-2 and the anti-B7-2 antibody, and detecting the presence or absence of the complex formation. The presence of the complex indicates the presence of B7-2 in the sample.

The invention relates to methods for treating a patient having a disease comprising administering a therapeutically effective amount of a humanized immunoglobulin specific to B7-1 and a therapeutically effective amount of a humanized immunoglobulin specific to B7-2. The diseases, as described herein, include, for example, autoimmune diseases, infectious diseases, asthma, inflammatory disorders, systemic lupus erythematosus, diabetes mellitus, insulitis, arthritis, inflammatory bowel disease, inflammatory dermatitis, and multiple sclerosis. This method also pertains to modulating the immune response of a patient having a transplanted organ, tissue, cell or the like comprising administering an effective amount of a humanized immunoglobulin that binds to B7-1 and a humanized immunoglobulin that binds to B7-2. Such diseases are described herein.

The invention also pertains to methods for transplanting cells (e.g., bone marrow, or blood cells or components) to a patient in need thereof comprising obtaining cells (e.g., bone marrow, or blood cells or components) from a donor, contacting the cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2 and recipient cells, thereby obtaining a mixture. The immunoglobulins and the recipient cells are maintained for a period of time sufficient for tolerance induction. The mixture (e.g., bone marrow or blood cell composition) is then introduced into the patient. The recipient cells comprise a lymphocyte antigen (e.g. lymphocytes that express class 1 antigens (MHCI) or peripheral blood lymphocyte (PBL)). Instead of using recipient cells, the method also comprise utilizing tissue, organs or cells that express MHC Class

I antigens, B7-1 and/or B7-2 molecules. The cells can be engineered to express recipient molecules. The cells from the donor can be bone marrow cells or cells/components from blood (e.g., stem cells or immature cells). The B7 immunoglobulins are in contact with the donor bone marrow and the recipient cells for a

5   period of time that is long enough to induce tolerance induction (e.g., about 1 to 48 hours, and, preferably about 36 hours). A patient in need of such a transplant is one who has a disease that is benefitted by or treatable with a bone marrow transplant. Such diseases, for example, are proliferative diseases (e.g. leukemia, lymphoma and cancer), anemia (e.g. sickle-cell anemia, thalassemia, and aplastic anemia) and myeloid dysplasia

10   syndrome (MDS).

The invention includes methods for transplanting bone marrow to a patient having a disease (e.g., proliferative diseases such as leukemia, lymphoma, cancer; anemia (e.g., sickle-cell anemia, thalassemia, and aplastic anemia) and myeloid dysplasia syndrome that is treated with a bone marrow transplant comprising obtaining

15   bone marrow from a donor, and contacting the bone marrow with an immunoglobulin specific to B7-1 and/or an immunoglobulin specific to B7-2 and recipient cells (e.g., lymphocyte). The bone marrow, immunoglobulin(s) and recipient cells are in contact for a period of time sufficient for tolerance induction (e.g., about 1-48 hours, preferably about 36 hours). The method then comprises re-introducing the treated bone marrow to

20   the patient.

Advantages of the invention include the ability to regulate or modulate the B7 costimulatory pathway. Manipulation of this costimulatory pathway with a humanized anti-B7-2 and/or anti-B7-1 antibody provides methods of treatments for various diseases. The humanized B7-2 antibody maintains about the same specificity for B7-2

25   as the murine 3D1 antibody, but with a reduced immunogenicity in humans. Accordingly, the invention can advantageously be used to treat immune-related diseases/disorders or diseases in which the B7-2 molecule plays an important role. Particularly, the invention relates to methods for treating infectious or autoimmune

diseases and methods for modulating the immune response for patients with transplanted organs, tissue or cells.

BRIEF DESCRIPTION OF THE FIGURES

The foregoing and other embodiments, features and advantages of the invention

5   will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying figures.

Figure 1A is a sequence listing illustrating the heavy chain variable region nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of the murine 3D1 antibody, wherein the amino acid sequences of the CDRs (CDR1, CDR2

10   and CDR3) are underlined and the first amino acids of the mature chains are double underlined.

Figure 1B is a sequence listing illustrating the light chain variable region nucleic acid and amino acid sequences (SEQ ID NOS: 3 and 4, respectively) of the murine 3D1 antibody wherein, the nucleic and amino acid sequences of the CDRs (CDR1, CDR2

15   and CDR3) are underlined and the first amino acids of the mature chains are double underlined.

Figure 2A is a sequence listing illustrating the heavy chain variable region nucleic acid and amino acid sequences (SEQ ID NOs: 5 and 6, respectively) of the humanized 3D1 antibody, wherein the nucleic and amino acid sequences of the CDRs

20   (CDR1, CDR2 and CDR3) are underlined and the first amino acids of the mature chains are double underlined.

Figure 2B contains the light chain variable region nucleic acid and amino acid sequences (SEQ ID NOs: 7 and 8, respectively) of the humanized 3D1 antibody, wherein the nucleic and amino acid sequences of CDR1, CDR2 and CDR3. The CDRs

25   are underlined and the first amino acids of the mature chains are double underlined.

Figure 3 is a graph of competitive binding assays. The graph depicts the results of a competitive binding assay of murine or humanized anti-human B7-2 mAbs to CHO expressing rhB7-2 (CHO/hB7-2) on their surface. Increasing concentrations of

unlabelled competitor antibodies were incubated with CHO/hB7-2 cells in the presence of radiolabelled tracer murine anti-human B7-2 mAb and the ratio of bound/free antibody was determined.

Figure 4 is a graph depicting the results of a direct binding assay of murine or humanized anti-human B7-2 mAbs to CHO/hB7-2 cells. Increasing concentrations of radiolabelled antibodies were incubated with CHO or CHO/hB7-2 cells and the amount of specific antibody bound to the CHO/hB7-2 cells was determined.

Figure 5 is a graph depicting the results of a T cell proliferation assay. Increasing concentrations of murine or humanized anti-human B7-2 mAbs were added to CD28$^+$ human T cells stimulated with PMA and CHO/hB7-2 cells and the inhibition of T cell proliferation by these mAbs was determined.

Figure 6 is a graph depicting the results of a one way mixed lymphocyte reaction (MLR) assay. Fixed concentrations of murine or humanized anti-human B7-2 (IgG2.M3 isotype) or hCTLA4Ig were added to a mixture of human responder and stimulator PBLs and the proliferation of the responder PBLs was determined on days 3, 4, and 5 by the addition of radiolabelled thymidine.

Figure 7 is a graph depicting the results of a one way secondary MLR assay using PBLs from a primary MLR as responders and PBLs from the same or a different individual as in the primary MLR as stimulators. The humanized anti-human B7-2 mAb (IgG2.M3 isotype) was added to the primary MLR only. Proliferation of the responder PBLs in the secondary MLR was determined on days 3, 4, and 5 by the addition of radiolabelled thymidine.

Figure 8 is a graph depicting the results of a one way secondary MLR assay using PBLs from a primary MLR as responders and PBLs from the same or a different individual as in the primary MLR as stimulators. The humanized anti-human B7-1 and B7-2 mAbs (IgG2.M3 isotype) were added to the primary MLR only. Proliferation of the responder PBLs in the secondary MLR was determined on days 3, 4, and 5 by the addition of radiolabelled thymidine.

Figure 9 is a graph depicting the anti-tetanus response in non-human primates immunized with tetanus toxoid. Cynomolgus monkeys were immunized with purified tetanus toxoid and treated with humanized anti-B7-1 and humanized anti-B7-2 (IgG2.M3 isotype) antibodies. Serum anti-tetanus antibody titers (IgM & IgG) were measured weekly over a 12 week period.

Figure 10 is a graph showing the serum concentration of anti-B7-1 and anti-B7-2 (IgG2.M3 isotype) mAbs at various times after administration of an I.V. dose of 10mg/Kg.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to a humanized immunoglobulin having binding specificity for B7-2, comprising an antigen binding region of nonhuman origin and at least a portion of an immunoglobulin of human origin. Preferably, the humanized immunoglobulins can bind B7-2 with an affinity of at least about $10^7 M^{-1}$, preferably at least about $10^8 M^{-1}$, and more preferably at least about $10^9 M^{-1}$. In one embodiment, the humanized immunoglobulin includes an antigen binding region of nonhuman origin which binds B7-2 and a constant region derived from a human constant region. The human constant region can have non-human residues in the framework region. In another embodiment, the humanized immunoglobulin which binds B7-2 comprises a complementarity determining region (one or more) of nonhuman origin and a variable framework region (one or more) of human origin, and optionally, a constant region of human origin. Optionally, the FR region of the immunoglobulin can comprise residues of non-human origin. For example, the humanized immunoglobulin can comprise a heavy chain and a light chain, wherein the light chain comprises a complementarity determining region derived from an antibody of nonhuman origin which binds B7-2 and a framework region derived from a light chain of human origin, and the heavy chain comprises a complementarity determining region derived from an antibody of nonhuman origin which binds B7-2 and a framework region derived from a heavy chain

of human origin. Also, the invention, individually or in a functional combination, embodies the light chain, the heavy chain, the variable region, the variable light chain and the variable heavy chain.

The invention relates to a humanized B7-2 antibody that possesses substantially
5   the same binding specificity as the murine B7-2 antibody (e.g., 3D1) from which the humanized antibody is made, but with reduced immunogenicity in primates (e.g., humans). The humanized B7-2 antibody has about a lessor, substantially the same, or greater binding affinity as the murine counterpart. See Figures 3 and 4.

Naturally occurring immunoglobulins have a common core structure in which
10 two identical light chains (about 24 kD) and two identical heavy chains (about 55 or 70 kD) form a tetramer. The amino-terminal portion of each chain is known as the variable (V) region, also referred to as the "antigen binding" region, and can be distinguished from the more conserved constant (C) regions of the remainder of each chain. Within the variable region of the light chain is a C-terminal portion known as the J region.
15 Within the variable region of the heavy chain, there is a D region in addition to the J region. Most of the amino acid sequence variation in immunoglobulins is confined to three separate locations in the V regions known as hypervariable regions or complementarity determining regions (CDRs) which are directly involved in antigen binding. The variable region is the portion of the antibody that binds to the antigen.
20 The constant region allows for various functions such as the ability to bind to Fc receptors on phagocytic cells, placental cells, mast cells, etc. The light and heavy chains each have a variable region and a constant region. Accordingly, the invention relates to a humanized immunoglobulin having binding specificity to B7-2. The humanized immunoglobulin comprises a light chain and a heavy chain in which two light chains
25 and two heavy chains form the tetramer.

The variable region further constitutes two types of regions, a framework region (FR) and a complementarity determining region (CDR). CDRs are hypervariable regions that contain most of the amino acid sequence variation in between immunoglobulins. Proceeding from the amino-terminus, these regions are designated

CDR1, CDR2 and CDR3, respectively. See Figures 1A-1B and 2A-2B. The CDRs are connected by more conserved FRs. Proceeding from the amino-terminus, these regions are designated FR1, FR2, FR3, and FR4, respectively. The locations of CDR and FR regions and a numbering system have been defined by Kabat et al. (Kabat, E.A. et al.,

5   Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991); Kabat, E.A. Structural Concepts in Immunology and Immunochemistry, Second Edition, Holt, Rinehart and Winston, New York (1976); Kabat, E.A. Sequences of Immunoglobulin Chains: Tabulation and Analysis of Amino Acid Sequences of Precurrsors, V-regions,

10   C-regions, J-Chain and β2-Microglobulins, U.S. Department of Health, Education and Welfare, Public Health Service, (1979); Kabat, E.A. Structural Concepts in Immunology and Immunochemistry, Holt, Rinehart and Winston, New York (1968); Kabat, E.A. Experimental Immunochemistry, Second Edition, Springfield, Thomas (1967). During the process of humanizing an immunoglobulin, one or more of the CDRs from an

15   antibody having specificity for B7-2 from a non-human species is grafted into the FRs of a human antibody. In addition, certain non-human framework substitutes can be made according to the methods described herein. The resulting humanized antibody has CDRs from a non-human species such as a mouse and FRs from a human antibody, whereby the humanized antibody maintains its antigenic specificity and affinity to B7-2.

20   The invention also relates to a humanized immunoglobulin light chain or a humanized immunoglobulin heavy chain. In one embodiment, the invention relates to a humanized light chain comprising one or more light chain CDRs (e.g., CDR1 (SEQ ID NO: 16), CDR2 (SEQ ID NO: 18) and/or CDR3 (SEQ ID NO: 20)) of nonhuman origin and a human light chain framework region (See Figure 2B). In another embodiment, the

25   invention relates to a humanized immunoglobulin heavy chain comprising one or more heavy chain CDRs (e.g., CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 12), and/or CDR3 (SEQ ID NO: 14)) of nonhuman origin and a human heavy chain framework region (See Figure 2A). The CDRs can be derived from a nonhuman immunoglobulin

such as murine heavy (e.g., SEQ ID NO: 1, Figure 1A) and light (e.g., SEQ ID NO: 3, Figure 1B) variable region chains which are specific to B7-2.

The invention also embodies the humanized anti-B7-2 antibody expressed by a cell line deposited with the A.T.C.C., 10801 University Boulevard, Manassas, VA

5   02110-2209, on May 5, 1998, A.T.C.C. No: CRL-12524. The cell line which expresses the humanized anti-B7-2 antibody, deposited with the A.T.C.C., is designated as a recombinant CHO cell line (PA-CHO-DUKX-1538) expressing the humanized anti-human B7-2 (CD86) monoclonal antibody (#HF2-3D1) of the IgG2.M3 isotype.

Human immunoglobulins can be divided into classes and subclasses, depending

10   on the isotype of the heavy chain. The classes include IgG, IgM, IgA, IgD and IgE, in which the heavy chains are of the gamma (γ), mu (μ), alpha (α), delta (δ) or epsilon (ϵ) type, respectively. Subclasses include IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, in which the heavy chains are of the γ1, γ2, γ3, γ4, α1 and α2 type, respectively. Human immunoglobulin molecules of a selected class or subclass may contain either a

15   kappa (κ) or lambda (λ) light chain. See e.g., *Cellular and Molecular Immunology*, Wonsiewicz, M.J., Ed., Chapter 45, pp. 41-50, W. B. Saunders Co, Philadelphia, PA (1991); Nisonoff, A., *Introduction to Molecular Immunology*, 2nd Ed., Chapter 4, pp. 45-65, Sinauer Associates, Inc., Sunderland, MA (1984).

The terms "HF2.3D1" and "3D1" refer to a murine immunoglobulin specific to

20   B7-2. The terms "humanized HF2.3D1," "humanized 3D1" and "hu3D1" refer to a humanized immunoglobulin specific to B7-2.

The terms "immunoglobulin" or "antibody" include whole antibodies and biologically functional fragments thereof. Such biologically functional fragments retain at least one antigen binding function of a corresponding full-length antibody (e.g., for

25   B7-2) and preferably, retain the ability to inhibit the interaction of B7-2 with one or more of its receptors (e.g., CD28, CTLA-4). In a preferred embodiment, biologically functional fragments can inhibit binding of B7-2 for manipulation of the co-stimulatory pathway. Examples of biologically functional antibody fragments which can be used include fragments capable of binding to an B7-2, such as single chain antibodies, Fv,

Fab, Fab' and F(ab')$_2$ fragments. Such fragments can be produced by enzymatic cleavage or by recombinant techniques. For instance, papain or pepsin cleavage can be used to generate Fab or F(ab')$_2$ fragments, respectively. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop

5   codons have been introduced upstream of the natural stop site. For example, a chimeric gene encoding the heavy chain of an F(ab')$_2$ fragment can be designed to include DNA sequences encoding the CH$_1$ domain and hinge region of the heavy chain. The invention includes single chain antibodies (e.g., a single chain FV) that contain both portions of the heavy and light chains.

10   The term "humanized immunoglobulin" as used herein refers to an immunoglobulin comprising portions of immunoglobulins of different origin, wherein at least one portion is of human origin. For example, the humanized antibody can comprise portions derived from an immunoglobulin of nonhuman origin with the requisite specificity, such as a mouse, and from immunoglobulin sequences of human

15   origin (e.g., chimeric immunoglobulin). These portions can be joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain). Another example of a humanized immunoglobulin of the invention is an

20   immunoglobulin containing one or more immunoglobulin chains comprising a CDR derived from an antibody of nonhuman origin and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes). Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin. See, e.g., Cabilly *et al.*, U.S.

25   Patent No. 4,816,567; Cabilly *et al.*, European Patent No. 0,125,023 B1; Boss *et al.*, U.S. Patent No. 4,816,397; Boss *et al.*, European Patent No. 0,120,694 B1; Neuberger, M.S. *et al.*, WO 86/01533; Neuberger, M.S. *et al.*, European Patent No. 0,194,276 B1; Winter, U.S. Patent No. 5,225,539; Winter, European Patent No. 0,239,400 B1; Padlan, E.A. *et al.*, European Patent Application No. 0,519,596 A1. See also, Ladner *et al.*,

U.S. Patent No. 4,946,778; Huston, U.S. Patent No. 5,476,786; and Bird, R.E. *et al.,* *Science, 242:* 423-426 (1988)), regarding single chain antibodies.

As embodied in the exemplified antibody of the present invention, the term "humanized immunoglobulin" also refers to an immunoglobulin comprising a human

5   framework, at least one CDR from a non-human antibody, and in which any constant region present is substantially identical to a human immunoglobulin constant region, e.g., at least about 60-90%, preferably at least 95% identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDR's, are substantially identical to corresponding parts of one or more native human immunoglobulin sequences. In some

10   instances, the humanized immunoglobulin, in addition to CDRs from a non-human antibody, would include additional non-human residues in the human framework region.

The design of humanized immunoglobulins can be carried out as follows. When an amino acid falls under the following categories, the framework amino acid of a human immunoglobulin to be used (acceptor immunoglobulin) is replaced by a

15   framework amino acid from a CDR-providing non-human immunoglobulin (donor immunoglobulin):

(a)   the amino acid in the human framework region of the acceptor immunoglobulin is unusual for human immunoglobulin at that position, whereas the corresponding amino acid in the donor immunoglobulin is

20   typical for human immunoglobulin in that position:

(b)   the position of the amino acid is immediately adjacent to one of the CDR's; or

(c)   the amino acid is capable of interacting with the CDR's in a tertiary structure immunoglobulin model (see, Queen et al., op. cit., and Co et al.,

25   Proc. Natl. Acad. Sci. USA 88, 2869 (1991)).

For a detailed description of the production of humanized immunoglobulins, See Queen et al., op. cit. and Co et al, op. cit. and U.S. Patents 5,585,089; 5,693,762, 5,693,761, and 5,530,101.

Usually, the CDR regions in humanized antibodies are substantially identical, and more usually, identical to the corresponding CDR regions in the mouse antibody from which they were derived. Although not usually desirable, it is sometimes possible to make one or more conservative amino acid substitutions of CDR residues without
5 appreciably affecting the binding affinity of the resulting humanized immunoglobulin. Occasionally, substitutions of CDR regions can enhance binding affinity.

Other than for the specific amino acid substitutions discussed above, the framework regions of humanized immunoglobulins are usually substantially identical, and more usually, identical to the framework regions of the human antibodies from
10 which they were derived. Of course, many of the amino acids in the framework region make little or no direct contribution to the specificity or affinity of an antibody. Thus, many individual conservative substitutions of framework residues can be tolerated without appreciable change of the specificity or affinity of the resulting humanized immunoglobulin.

15 The antigen binding region of the humanized immunoglobulin (the non-human portion) can be derived from an immunoglobulin of nonhuman origin, referred to as a donor immunoglobulin, having specificity for B7-2. For example, a suitable antigen binding region can be derived from the murine HF2.3D1 monoclonal antibody. U.S. Serial No. 08/101,624, filed on July 26, 1993, 08/109,393, filed August 19, 1993 and
20 08/147,773, filed November 3, 1993, entitled, "B7-2:CTLA4/CD28 Counter Receptor". See also, Freeman, *et al.*, WO 95/03408, " B7-2: CTLA4/CD 28 Counter Receptor, published on February 2, 1995. Other sources include B7-2-specific antibodies obtained from nonhuman sources, such as rodent (e.g., mouse and rat), rabbit, pig, goat or non-human primate (e.g., monkey) or camelid animals (e.g., camels and llamas).

25 Additionally, other polyclonal or monoclonal antibodies, such as antibodies which bind to the same or similar epitope as the murine HF2.3D1 antibody, can be made (e.g., Kohler *et al.*, *Nature, 256*:495-497 (1975); Harlow *et al.*, 1988, Antibodies: A Laboratory Manual, (Cold Spring Harbor, NY); and Current Protocols in Molecular Biology, Vol. 2 (Supplement 27, Summer '94), Ausubel *et al.*, Eds. (John Wiley &

Sons: New York, NY), Chapter 11 (1991)). For example, antibodies can be raised against an appropriate immunogen in a suitable mammal such as a mouse, rat, rabbit, sheep, or camelid. Cells bearing B7-2, membrane fractions containing B7-2, immunogenic fragments of B7-2, and a B7-2 peptide conjugated to a suitable carrier are

5   examples of suitable immunogens (e.g., DNA or peptide immunogens). Antibody-producing cells (e.g., a lymphocyte) can be isolated, for example, from the lymph nodes or spleen of an immunized animal. The cells can then be fused to a suitable immortalized cell (e.g., a myeloma cell line), thereby forming a hybridoma. Fused cells can be isolated employing selective culturing techniques. Cells which produce

10   antibodies with the desired specificity can be selected by a suitable assay, such as an ELISA. Immunoglobulins of nonhuman origin having binding specificity for B7-2 can also be obtained from antibody libraries, such as a phage library comprising nonhuman Fab molecules. Humanized immunoglobulins can be made using molecular biology techniques, Abgenics, or CAT techniques.

15   In one embodiment, the antigen binding region of the humanized immunoglobulin comprises a CDR of nonhuman origin. In this embodiment, the humanized immunoglobulin having binding specificity for B7-2 comprises at least one CDR of nonhuman origin. For example, CDRs can be derived from the light and heavy chain variable regions of immunoglobulins of nonhuman origin, such that a humanized

20   immunoglobulin includes substantially the heavy chain CDR1 (e.g., SEQ ID NO: 10), CDR2 (e.g., SEQ ID NO: 12) and/or CDR3 (e.g., SEQ ID NO: 14) amino acid sequences, and/or light chain CDR1 (e.g., SEQ ID NO: 16), CDR2 (e.g., SEQ ID NO: 18) and/or CDR3 (e.g., SEQ ID NO: 20) amino acid sequences, from one or more immunoglobulins of nonhuman origin, and the resulting humanized immunoglobulin

25   has binding specificity for B7-2. All three CDRs of a selected chain can be substantially the same as the CDRs of the corresponding chain of a donor, and preferably, all three CDRs of the light and heavy chains are substantially the same as the CDRs of the corresponding donor chain. The nucleic acid sequences of the heavy chain CDR1 (e.g., SEQ ID NO: 9), CDR2 (e.g., SEQ ID NO: 11) and CDR3 (e.g., SEQ ID NO: 13) and/or

light chain CDR1 (e.g., SEQ ID NO: 15), CDR2 (e.g., SEQ ID NO: 17), and CDR3 (e.g., SEQ ID NO: 19) can also be used in grafting the CDRs into the human framework.

In another embodiment, the invention pertains to a humanized immunoglobulin having a binding specificity for B7-2 comprising a heavy chain and a light chain. The light chain can comprise a CDR derived from an antibody of nonhuman origin which binds B7-2 and a FR derived from a light chain of human origin. For example, the light chain can comprise CDR1, CDR2 and/or CDR3 which have the amino acid sequence set forth below or an amino acid substantially the same as the amino acid sequence such that the antibody specifically binds to the B7-2: CDR1 KSSQSLLNSRTRENYLA (SEQ ID NO: 16), CDR2 WASTRES (SEQ ID NO: 18), and CDR3 TQSYNLYT (SEQ ID NO: 20). The heavy chain can comprise a CDR derived from an antibody of nonhuman origin which binds B7-2 and a FR derived from a heavy chain of human origin. For example, the heavy chain can comprise CDR1, CDR2 and CDR3 which have the amino acid sequence set forth below or an amino acid substantially the same as said amino acid sequence such that the antibody specifically binds to the B7-2: heavy chain: CDR1 DYAIQ (SEQ ID NO: 10), CDR2 VINIYYDNTNYNQKFKG (SEQ ID NO: 12), CDR3 AAWYMDY (SEQ ID NO: 14).

An embodiment of the invention is a humanized immunoglobulin which specifically binds to B7-2 and comprises a humanized light chain comprising three light chain CDRs from the mouse 3D1 antibody and a light chain variable region framework sequence from a human immunoglobulin light chain. The invention further comprises a humanized heavy chain that comprises three heavy chain CDRs from the mouse 3D1 antibody and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain. The mouse 3D1 antibody can further have a mature light chain variable domain as shown in Figure 1B (SEQ ID NO.: 4) and a mature heavy chain variable domain as shown in Figure 1A (SEQ ID NO.: 2).

The portion of the humanized immunoglobulin or immunoglobulin chain which is of human origin (the human portion) can be derived from any suitable human

immunoglobulin or immunoglobulin chain. For example, a human constant region or portion thereof, if present, can be derived from the κ or λ light chains, and/or the γ (*e.g.*, γ1, γ2, γ3, γ4), μ, α (*e.g.*, α1, α2), δ or ε heavy chains of human antibodies, including allelic variants. A particular constant region, such as IgG2 or IgG4, variants

5   or portions thereof can be selected to tailor effector function. For example, a mutated constant region, also referred to as a "variant," can be incorporated into a fusion protein to minimize binding to Fc receptors and/or ability to fix complement (see *e.g.*, Winter *et al.*, U.S. Patent No. 5,648,260 and 5,624,821; GB 2,209,757 B; Morrison *et al.*, WO 89/07142; Morgan *et al.*, WO 94/29351, December 22, 1994). In addition, a mutated

10   IgG2 Fc domain can be created that reduces the mitogenic response, as compared to natural FC regions (see e.g., Tso *et al.*, U.S. Patent No. 5,834,597, the teachings of which are incorporated by reference herein in their entirety). See Example 3 for mutations performed to the humanized anti-B7-2 antibody.

If present, human FRs are preferably derived from a human antibody variable

15   region having sequence similarity to the analogous or equivalent region of the antigen binding region donor. Other sources of FRs for portions of human origin of a humanized immunoglobulin include human variable consensus sequences (See, Kettleborough, C.A. *et al.*, *Protein Engineering 4*:773-783 (1991); Queen *et al.*, U.S. patent Nos: 5,585,089, 5,693,762 and 5,693,761, the teachings all of which are

20   incorporated by reference herein in their entirety). For example, the sequence of the antibody or variable region used to obtain the nonhuman portion can be compared to human sequences as described in Kabat, E.A., *et al., Sequences of Proteins of Immunological Interest,* Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991). In a preferred embodiment, the FRs of a

25   humanized immunoglobulin chain are derived from a human variable region having at least about 60% overall sequence identity, and preferably at least about 80% overall sequence identity, with the variable region of the nonhuman donor (e.g., murine HF2.3D1 antibody). For example, the overall sequence identity between the mouse HF2.3D1 and human H2F light chain variable framework regions is 82.5%, and the

overall sequence identity between the mouse HF2.3D1 and human I2R heavy chain variable framework regions is 62.5%.

The phrase "substantially identical," in context of two nucleic acids or polypeptides (e.g., DNAs encoding a humanized immunoglobulin or the amino acid
5 sequence of the humanized immunoglobulin) refers to two or more sequences or subsequences that have at least about 80%, most preferably 90-95% or higher nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using the following sequence comparison method and/or by visual inspection. Such "substantially identical" sequences are typically considered
10 to be homologous. Preferably, the "substantial identity" exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues, or over the full length of the two sequences to be compared. As described below, any two antibody sequences can only be aligned in one
15 way, by using the numbering scheme in Kabat. Therefore, for antibodies, percent identity has a unique and well-defined meaning.

Amino acids from the variable regions of the mature heavy and light chains of immunoglobulins are designated Hx and Lx respectively, where x is a number designating the position of an amino acid according to the scheme of Kabat, *Sequences*
20 *of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, MD, 1987 and 1991). Kabat lists many amino acid sequences for antibodies for each subgroup, and lists the most commonly occurring amino acid for each residue position in that subgroup. Kabat uses a method for assigning a residue number to each amino acid in a listed sequence, and this method for assigning residue numbers has become
25 standard in the field. Kabat's scheme is extendible to other antibodies not included in his compendium by aligning the antibody in question with one of the consensus sequences in Kabat. The use of the Kabat numbering system readily identifies amino acids at equivalent positions in different antibodies. For example, an amino acid at the

L50 position of a human antibody occupies the equivalent position to an amino acid position L50 of a mouse antibody.

The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites.

Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See generally, *Fundamental Immunology,* Paul, W., ed., 3rd ed. Raven Press, N.Y., 1993, Ch. 9).

From N-terminal to C-terminal, both light and heavy chain variable regions comprise alternating framework and (CDRs)" FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each region is in accordance with the definitions of Kabat (1987) and (1991), *supra* and/or Chothia & Lesk, *J. Mol. Biol.* 196:901-917 (1987); Chothia *et al., Nature* 342:878-883 (1989).

In one embodiment, the humanized immunoglobulin comprises at least one of the FRs derived from one or more chains of an antibody of human origin. Thus, the FR can include a FR1, FR2, FR3 and/or FR4 derived from one or more antibodies of human origin. Preferably, the human portion of a selected humanized chain includes FR1, FR2, FR3 and/or FR4 derived from a variable region of human origin (e.g., from a human immunoglobulin chain, from a human consensus sequence). In a preferred embodiment,

the FRs for the light chain variable region are from the H2F human antibody and the FRs for the heavy chain variable region are from the I2R human antibody.

The immunoglobulin portions of nonhuman and human origin for use in the invention have sequences that are identical to immunoglobulins or immunoglobulin portions from which they are derived, or to variants thereof. Such variants include mutants differing by the addition, deletion, or substitution of one or more residues. As indicated above, the CDRs which are of nonhuman origin are substantially the same as in the nonhuman donor, and preferably are identical to the CDRs of the nonhuman donor. As described herein, changes in the FR, such as those which substitute a residue of the FR of human origin with a residue from the corresponding position of the donor can be made. One or more mutations in the FR can be made, including deletions, insertions and substitutions of one or more amino acids. Several such substitutions are described in the design of a humanized HF2.3D1 antibody in Example 2. For a selected humanized antibody or chain, framework mutations can be designed as described herein. Preferably, the humanized immunoglobulins can bind B7-2 with an affinity similar to or better than that of the nonhuman donor. Variants can be produced by a variety of suitable methods, including mutagenesis of nonhuman donor or acceptor human chains.

The humanized immunoglobulins of the invention have binding specificity for human B7-2, and include humanized immunoglobulins (including fragments) which can bind determinants of B7-2. In a preferred embodiment, the humanized immunoglobulin of the present invention has at least one functional characteristic of murine HF2.3D1 antibody, such as binding function (e.g., having specificity for B7-2, having the same or similar epitopic specificity), and/or inhibitory function (e.g., the ability to inhibit the binding of a cell bearing CD28 or CTLA-4 to the B7-2 ligand). Thus, preferred humanized immunoglobulins can have the binding specificity of the murine HF2.3D1 antibody, the epitopic specificity of the murine HF2.3D1 antibody (e.g., can compete with murine HF2.3D1, a chimeric HF2.3D1 antibody, or humanized HF2.3D1 for binding to B7-2) and/or inhibitory function.

The binding function of a humanized immunoglobulin having binding specificity for B7-2 can be detected by standard immunological methods, for example using assays which monitor formation of a complex between humanized immunoglobulin and B7-2 (e.g., a membrane fraction comprising B7-2, or human lymphocyte cell line or

5   recombinant host cell comprising nucleic acid which expresses B7-2).

Binding and/or adhesion assays or other suitable methods can also be used in procedures for the identification and/or isolation of humanized immunoglobulins (e.g., from a library) with the requisite specificity (e.g., an assay which monitors adhesion between a cell bearing a B7-2 receptor and B7-2, or other suitable methods).

10   The immunoglobulin portions of nonhuman and human origin for use in the invention include light chains, heavy chains and portions of light and heavy chains. These immunoglobulin portions can be obtained or derived from immunoglobulins (e.g., by de novo synthesis of a portion), or nucleic acids encoding an immunoglobulin or chain thereof having the desired property (e.g., binds B7-2, sequence similarity) can

15   be produced and expressed. Humanized immunoglobulins comprising the desired portions (e.g., antigen binding region, CDR, FR, C region) of human and nonhuman origin can be produced using synthetic and/or recombinant nucleic acids to prepare genes (e.g., cDNA) encoding the desired humanized chain. To prepare a portion of a chain, one or more stop codons can be introduced at the desired position. For example,

20   nucleic acid sequences coding for newly designed humanized variable regions can be constructed using PCR mutagenesis methods to alter existing DNA sequences (see e.g., Kamman, M., *et al.*, *Nucl. Acids Res. 17*:5404 (1989)). PCR primers coding for the new CDRs can be hybridized to a DNA template of a previously humanized variable region which is based on the same, or a very similar, human variable region (Sato, K., *et al.*,

25   *Cancer Research 53*:851-856 (1993)). If a similar DNA sequence is not available for use as a template, a nucleic acid comprising a sequence encoding a variable region sequence can be constructed from synthetic oligonucleotides (see e.g., Kolbinger, F., *Protein Engineering 8*:971-980 (1993)). A sequence encoding a signal peptide can also be incorporated into the nucleic acid (e.g., on synthesis, upon insertion into a vector). If

the natural signal peptide sequence is unavailable, a signal peptide sequence from another antibody can be used (see, e.g., Kettleborough, C.A., *Protein Engineering* *4*:773-783 (1991)). Using these methods, methods described herein or other suitable methods, variants can be readily produced. In one embodiment, cloned variable regions

5   can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber *et al.*, U.S. 5,514,548; Hoogengoom *et al.*, WO 93/06213, published April 1, 1993)).

Nucleic Acids and Constructs Comprising Same:

        The invention also relates to isolated and/or recombinant (including, e.g.,

10   essentially pure) nucleic acids comprising sequences which encode a humanized immunoglobulin or humanized immunoglobulin light or heavy chain of the present invention.

        Nucleic acids referred to herein as "isolated" are nucleic acids which have been separated away from the nucleic acids of the genomic DNA or cellular RNA of their

15   source of origin (e.g., as it exists in cells or in a mixture of nucleic acids such as a library), and include nucleic acids obtained by methods described herein or other suitable methods, including essentially pure nucleic acids, nucleic acids produced by chemical synthesis, by combinations of biological and chemical methods, and recombinant nucleic acids which are isolated (see e.g., Daugherty, B.L. *et al.*, *Nucleic*

20   *Acids Res.*, *19(9):* 2471-2476 (1991); Lewis, A.P. and J.S. Crowe, *Gene, 101:* 297-302 (1991)).

        Nucleic acids referred to herein as "recombinant" are nucleic acids which have been produced by recombinant DNA methodology, including those nucleic acids that are generated by procedures which rely upon a method of artificial recombination, such

25   as the polymerase chain reaction (PCR) and/or cloning into a vector (e.g., plasmid) using restriction enzymes. "Recombinant" nucleic acids are also those that result from recombination events that occur through the natural mechanisms of cells, but are

selected for after the introduction to the cells of nucleic acids designed to allow and make probable a desired recombination event.

The invention also relates more specifically to isolated and/or recombinant nucleic acids comprising a nucleotide sequence which encodes a humanized HF2.3D1

5   immunoglobulin, also referred to as humanized 3D1 (e.g., a humanized immunoglobulin of the invention in which the nonhuman portion is derived from the murine HF2.3D1 monoclonal antibody) or chain thereof. In one embodiment, the light chain comprises three complementarity determining regions derived from the light chain of the HF2.3D1 antibody, and the heavy chain comprises three complementarity determining regions

10   derived from the heavy chain of the HF2.3D1 antibody. Such nucleic acids include, for example, (a) a nucleic acid comprising a sequence which encodes a polypeptide comprising the amino acid sequence of the heavy chain variable region of a humanized HF2.3D1 immunoglobulin (e.g., SEQ ID NO: 5, See Figure 2A), (b) a nucleic acid comprising a sequence which encodes a polypeptide comprising the amino acid

15   sequence of the light chain variable region of a humanized HF2.3D1 immunoglobulin (e.g., SEQ ID NO: 7, See Figure 2B), (c) a nucleic acid comprising a sequence which encodes at least a functional portion of the light or heavy chain variable region of a humanized HF2.3D1 immunoglobulin (e.g., a portion sufficient for antigen binding of a humanized immunoglobulin which comprises the chain). Due to the degeneracy of the

20   genetic code, a variety of nucleic acids can be made which encode a selected polypeptide. In one embodiment, the nucleic acid comprises the nucleotide sequence of the variable region as set forth or substantially as set forth in Figure 2A and/or Figure 2B, including double or single-stranded polynucleotides. Isolated and/or recombinant nucleic acids meeting these criteria can comprise nucleic acids encoding sequences

25   identical to sequences of humanized HF2.3D1 antibody or variants thereof, as discussed above.

Nucleic acids of the invention can be used in the production of humanized immunoglobulins having binding specificity for B7-2. For example, a nucleic acid (e.g., DNA) encoding a humanized immunoglobulin of the invention can be incorporated into

a suitable construct (e.g., a vector) for further manipulation of sequences or for production of the encoded polypeptide in suitable host cells.

Method of Producing Humanized Immunoglobulins Having Specificity for B7-2:

Another aspect of the invention relates to a method of preparing a humanized immunoglobulin which has binding specificity for B7-2. The humanized immunoglobulin can be obtained, for example, by the expression of one or more recombinant nucleic acids encoding a humanized immunoglobulin having binding specificity for B7-2 in a suitable host cell.

Constructs or expression vectors suitable for the expression of a humanized immunoglobulin having binding specificity for B7-2 are also provided. The constructs can be introduced into a suitable host cell, and cells which express a humanized immunoglobulin of the invention, can be produced and maintained in culture. Suitable host cells can be procaryotic, including bacterial cells such as *E. coli, B. subtilis* and or other suitable bacteria, or eucaryotic, such as fungal or yeast cells (e.g., *Pichia pastoris, Aspergillus species, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neurospora crassa*), or other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects (e.g., Sf9 insect cells (WO 94/26087, O'Connor, published November 24, 1994)) or mammals (e.g., COS cells, NSO cells, SP2/0, Chinese hamster ovary cells (CHO), HuT 78 cells, 293 cells). (See, e.g., Ausubel, F.M. *et al.,* eds. *Current Protocols in Molecular Biology,* Greene Publishing Associates and John Wiley & Sons Inc., (1993)).

Host cells which produce a humanized immunoglobulin having binding specificity for B7-2 can be produced as follows. For example, a nucleic acid encoding all or part of the coding sequence for the desired humanized immunoglobulin can be inserted into a nucleic acid vector, e.g., a DNA vector, such as a plasmid, virus or other suitable expression unit. A variety of vectors are available, including vectors which are maintained in single copy or multiple copy, or which become integrated into the host cell chromosome.

Suitable expression vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, terminator), and/or one or more translation signals; a

5   signal sequence or leader sequence for membrane targeting or secretion. In a construct, a signal sequence can be provided by the vector or other source. For example, the transcriptional and/or translational signals of an immunoglobulin can be used to direct expression.

A promoter can be provided for expression in a suitable host cell. Promoters can

10   be constitutive or inducible. For example, a promoter can be operably linked to a nucleic acid encoding a humanized immunoglobulin or immunoglobulin chain, such that it directs expression of the encoded polypeptide. A variety of suitable promoters for procaryotic (e.g., lac, tac, T3, T7 promoters for *E. coli*) and eucaryotic (e.g., yeast alcohol dehydrogenase (ADH1, SV40, CMV) hosts are available.

15   In addition, the expression vectors typically comprise a selectable marker for selection of host cells carrying the vector, and, in the case of replicable expression vector, an origin or replication. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in procaryotic (e.g., β-lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and

20   eucaryotic cells (e.g., neomycin (G418 or geneticin), gpt (mycophenolic acid), ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate in a variety of hosts. Genes encoding the gene product of auxotrophic markers of the host (e.g., *LEU2, URA3, HIS3*) are often used as selectable markers in yeast. Use of viral (e.g., baculovirus) or phage vectors, and

25   vectors which are capable of integrating into the genome of the host cell, such as retroviral vectors, are also contemplated. The invention also relates to cells carrying these expression vectors.

For example, a nucleic acid (e.g., one or more nucleic acids) encoding the heavy and light chains of a humanized immunoglobulin having binding specificity for B7-2, or

a construct (e.g., one or more constructs) comprising such nucleic acid(s), can be introduced into a suitable host cell by a method appropriate to the host cell selected (e.g., transformation, transfection, electroporation, infection), such that the nucleic acid(s) are operably linked to one or more expression control elements (e.g., in a vector,

5   in a construct created by processes in the cell, integrated into the host cell genome). Host cells can be maintained under conditions suitable for expression (e.g., in the presence of inducer, suitable media supplemented with appropriate salts, growth factors, antibiotic, nutritional supplements, etc.), whereby the encoded polypeptide(s) are produced. If desired, the encoded protein (e.g., humanized HF2.3D1 antibody) can be

10   isolated from (e.g., the host cells, medium, milk). This process encompasses expression in a host cell of a transgenic animal (see e.g., WO 92/03918, GenPharm International, published March 19, 1992).

Fusion proteins can be produced in which a humanized immunoglobulin or immunoglobulin chain is linked to a non-immunoglobulin moiety (e.g., a moiety which

15   does not occur in immunoglobulins as found in nature) in an N-terminal location, C-terminal location or internal to the fusion protein. For example, some embodiments can be produced by the insertion of a nucleic acid encoding immunoglobulin sequences into a suitable expression vector, such as a pET vector (e.g., pET-15b, Novagen), a phage vector (e.g., pCANTAB 5 E, Pharmacia), or other vector (e.g., pRIT2T Protein A fusion

20   vector, Pharmacia). The resulting construct can be introduced into a suitable host cell for expression. Upon expression, some fusion proteins can be isolated or purified from a cell lysate by means of a suitable affinity matrix (see e.g., *Current Protocols in Molecular Biology* (Ausubel, F.M. *et al.*, eds., Vol. 2, Suppl. 26, pp. 16.4.1-16.7.8 (1991)).

25   Therapeutic Methods and Compositions:

Two types of T-cells exist: helper T cells and cytotoxic T cells. The helper T cells is a mechanism that can recognize the antigen when the antigen is coupled with a major histocompatibility complex (MHC). Antigen presenting cells internalize an

antigen and re-express the antigen with the MHC molecule. Upon recognition of the antigen, a secretion of cytokines occur. Cytokine secretion activates B-lymphocytes and cytotoxic T cells, phagocytes and other cells. However, cytokine secretion and cellular proliferation require more than recognition of the antigen. Complete T-cell activation

5   requires a second signal referred to as the "costimulatory signal." These costimulatory signals serve to initiate, maintain, and regulate the activation cascade. An important costimulatory pathway is called the B7:CD28/CTLA-4 pathway.

The B7:CD28/CTLA-4 pathway involves two costimulatory ligands, B7-1 (CD80) and B7-2 (CD86). The B7-1 and B7-2 ligands which are present on the

10   antigen presenting cell each bind to two receptors on T-cells called CD28 and CTLA-4.

The expression of B7 antigens, B7-1 (CD80)and B7-2 (CD86), is tightly regulated. (Linsley, PS et al., Immunity 1:793-801 (1994). Unstimulated antigen-presenting cells generally do not express B7-1 and B7-2, except in dendritic cells. After activation, dendritic and epidermal Langerhans' cells, B cells, and macrophages up-

15   regulate the expression of B7-2 and B7-1. Additionally, B7-2 can be expressed on granulocytes and on T-cell molecules, and B7-1 is expressed in fibroblasts and T-cell molecules.

In most immune responses, B7-2 is induced earlier than B7-1 and rises to higher levels. B7-2 also affects the production of interleukin-4 (IL-4) and the generation of

20   type 2 helper cells. B7 molecules are also responsible for costimulating CD8 T cells in the absence of CD4 T cells which can be helpful in generating vaccines against melanoma. B7 molecules can costimulate natural killer cells and γ/δ T cells. Hence, modulation of B7 molecules is helpful in anti-tumor and anti-microbial immunity.

The B7:CD28/CTLA-4 pathway participates in various disease states including

25   the pathogenesis of infectious diseases, asthma, autoimmune diseases, inflammatory disorders, the rejection of grafted organs and graft versus host disease. This pathway also participates in prophylaxis and mechanisms that stimulate the immune system. Transfection with genes encoding costimulators, such as B7, are applicable for anti-tumor and anti-viral vaccines. Also, the B7 molecules participate in autoimmune

diseases such as systemic lupus erythematosus, diabetes mellitus, insulitis, arthritis, inflammatory bowel disease, inflammatory dermatitis (psoriasis vulgaris and atopic dermatitis), and multiple sclerosis. Reiser, Hans, M.D., *et al.*, Mechanisms of Disease, New England J. of Med., Vol 335, No. 18, 1369 (1996).

5   Accordingly, the invention encompasses methods for treating the disease, as described herein, comprising administering immunoglobulin(s) that binds to B7-1 and/or B7-2. The immunoglobulin should be administered in therapeutically effective amounts and, optionally, in a carrier. In addition to the diseases described herein, the immunoglobulin that bind B7-1 and/or B7-2 can be administered to a person having

10   transplanted tissue, organ or cells. Inhibiting the B7 pathway prevents or reduces the rejection of the transplanted tissue, organ or cell. The invention pertains to treating acute and/or chronic transplant rejection for a prolonged period of time (e.g., days, months, years).

Therefore, modulating or influencing the B7-2's role can be useful in treating

15   patients with these diseases. B7-2 modulation is also useful in treating patients with immune-related or autoimmune diseases and disorders in which B7-2 participates. The modulation of B7-2 can also be used for diseases related to or affected by IL-4 and/or the generation of type 2 helper cells. These disorders/diseases can be treated using an antibody specific to B7-2. Preferably, the antibody is a humanized antibody specific to

20   B7-2. Treatment of these diseases may be facilitated with co-administration of an anti-B7-2 antibody, including chimeric and humanized versions thereof, with an anti-B7-1 antibody, or antibodies to the corresponding receptors, CD28 and CTLA-4. Methods of treatment also involve co-administration of a humanized anti B7-2 antibody or humanized anti B7-1 antibody with other standard therapy drugs, such methotrexate,

25   cyclosporin, steroids, α CD40 ligands.

The invention includes methods for transplanting cells (e.g., blood cells or components, or bone marrow) to a patient in need thereof. A patient in need thereof is one, for example, having a disease that is treated with such a transplant (e.g., proliferative diseases such as leukemia, lymphoma, cancer), anemia such as sickle-cell

anemia, thalassemia, and aplastic anemia) and myeloid dysplasia syndrome). The method comprises obtaining cells from a donor. Generally, donor bone marrow contains both immature and mature lymphocytes. The blood cells from a donor can be stem cells or immature blood cells in addition to bone marrow cells. The cells of the

5 donor preferably comes from a person who has similar characteristics as the patient/recipient (e.g., the donor's bone marrow is a match to the patient's bone marrow). The characteristics that are analyzed to determine whether a donor is a match to the patient are MHC class 1 and 2 (e.g., HLA-A, HLA-B, and/or HLA-DR). The method involves contacting the cells (e.g., bone marrow or other blood components) with an

10 immunoglobulin specific to B7-1 and/or an immunoglobulin specific to B7-2 and recipient cells (e.g., lymphocyte from the patient) to obtain a mixture (e.g., treated cells). The donor cells, immunoglobulin(s) and recipient cells are in contact for a period of time sufficient for tolerance induction (e.g., about 1-48 hours, preferably about 36 hours). Tolerance induction (e.g., anergy) refers to the lack of responsiveness to an

15 antigen that has been induced with a treatment with B7-1 and/or B7-2 antibodies, such that the T-cell can no longer adequately or fully respond to that antigen. Example 9. The recipient cells (e.g., Peripheral Blood Lymphocytes (PBL), or lymphocytes that express class I antigens (MHC-I)) are radiated to prevent cells from dividing. A substitute for recipient cells can be tissue, organs or engineered cells that express MCH

20 class I antigens, and B7-1 and/or B7-2 molecules. The method then includes introducing the mixture (e.g., treated cells) or bone marrow to the patient. This method of treatment is aimed at preventing graft vs. host disease. For example, cells in the treated bone marrow become tolerant to recipient alloantigen thereby reducing or eliminating graft vs. host disease. Accordingly, the claimed methods include treatment,

25 preventing or aiding in the prevention of graft vs. host disease. The anti B7-1 and B7-2 antibodies reduce rejection of the donor bone marrow. However, the methods are able to reduce rejection without significantly compromising the patient's ability to detect and develop an immune response to other foreign cells and antigens. Hence, the methods

allows the transplantation to be recipient specific and reject foreign antigens without compromising the transplant. See Exemplification Section.

The terms "pharmaceutically acceptable carrier" or a "carrier" refer to any generally acceptable excipient or drug delivery device that is relatively inert and non-

5   toxic. A preferred embodiment is to administer the immunoglobulin, (e.g., tablet or capsule form). Exemplary carriers include calcium carbonate, sucrose, dextrose, mannose, albumin, starch, cellulose, silica gel, polyethylene glycol (PEG), dried skim milk, rice flour, magnesium stearate, and the like. Suitable formulations and additional carriers are described in Remington's Pharmaceutical Sciences, (17th Ed., Mack Pub.

10   Co., Easton, PA), the teachings of which are incorporated herein by reference in their entirety.

Suitable carriers (e.g., pharmaceutical carriers) also include, but are not limited to sterile water, salt solutions (such as Ringer's solution), alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate,

15   talc, silicic acid, viscous paraffin, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc. Such preparations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like which do not deleteriously react with the immunoglobulin. They can also be combined

20   where desired with other active substances, e.g., enzyme inhibitors, to reduce metabolic degradation. A carrier (e.g., a pharmaceutically acceptable carrier) is preferred, but not necessary to administer the immunoglobulin.

For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants,

25   including suppositories. In particular, carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-polyoxypropylene block polymers, and the like. Ampules are convenient unit dosages.

Immunoglobulins of the invention can be administered intravenously, parenterally, intramuscular, subcutaneously, orally, nasally, by inhalation, by implant, by injection, or by suppository. The composition can be administered in a single dose or in more than one dose over a period of time to confer the desired effect.

5   The actual effective amounts of immunoglobulin can vary according to the specific immunoglobulin being utilized, the particular composition formulated, the mode of administration and the age, weight and condition of the patient, for example. As used herein, an effective amount of the immunoglobulin is an amount which modulates or inhibits B7 molecules. Dosages for a particular patient can be determined

10   by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol).

The invention also pertains to methods for determining the presence, absence or level of B7-2 using a humanized anti-B7-2 antibody. The presence or absence of B7-2 can be detected in an assay (e.g., ELISA, radioimmunoassay (RIA) or FACS

15   Immunohistochemistry). The assay can be a direct detection or an indirect detection (e.g. a competitive assay).

For example, to determine the presence or absence of B7-2 using an ELISA assay in a suitable sample, the method comprises combining a suitable sample with a composition comprising a humanized or murine anti B7-2 antibody as detector (e.g.,

20   biotinylated anti B7-2 MAb and HRP-streptavidin, or HRP-conjugated anti-B7-2 Mab) and a solid support (e.g., a microtiter plate), having an anti-B7-2 capture antibody bound (directly or indirectly) thereto. The detector antibody can bind to a different B7-2 epitope from that recognized by the capture antibody, under conditions suitable for the formation of a complex between the anti-B7-2 antibodies and B7-2. The method further

25   comprises determining the formation of complex in the sample.

The presence of B7-2 can also be determined in a radioimmunoassay. For example, the presence of B7-2 can be assessed by an immunobinding assay comprising obtaining a sample, contacting the sample with a composition comprising an anti-B7-2 antibody (e.g., a humanized or murine anti-B7-2 antibody comprising a radioactive

label; or a humanized or murine anti-B7-2 antibody comprising a binding site for a second antibody which comprises a radioactive label), preferably in an amount in excess of that required to bind the B7-2, under conditions suitable for the formation of labeled complexes. The method further comprises determining (detecting or measuring) the

5   formation of complex in the samples.

EXEMPLIFICATION

        The present invention will now be illustrated by the following Examples, which are not intended to be limiting in any way.

Example 1: Cloning and Sequencing of Mouse 3D1 Variable Region cDNAs:

10   Mouse 3D1 (also referred to as HF2.3D1) heavy and light chain variable region cDNAs were cloned from mRNA isolated from hybridoma cells using anchored PCR (Co *et al., J. Immunol. 148*: 1149 (1992)). The 5' primers used annealed to the poly-dG tails added to the cDNA, and the 3' primers annealed to the constant regions. The amplified gene fragments were then inserted into the plasmid pUC18. Nucleotide

15   sequences were determined from several independent clones for both V_L and V_H cDNA. For the heavy chain, a single, unique sequence was identified, typical of a mouse heavy chain variable region. For the light chain, two unique sequences, both homologous to murine light chain variable region sequences, were identified. However, one sequence was not functional because of a missing nucleotide that caused a frame

20   shift at the V-J junction, and was identified as the non-productive allele. The other sequence was typical of a functional mouse kappa chain variable region. The variable region cDNA sequences of the heavy chain and the functional light chain and the translated amino acid sequences are shown in Figures 1A-1B. The mouse V_L sequence belongs to Kabat's mouse kappa chain subgroup I. The mouse V_H belongs to Kabat's

25   heavy chain subgroup II(A).

Example 2: Design of humanized 3D1 variable regions:

To retain the binding affinity of the mouse antibody in the humanized antibody, the general procedures of Queen *et al.* were followed (Queen *et al. Proc. Natl. Acad. Sci. USA 86*: 10029 (1989), U.S. Patent Nos. 5,585,089 and 5,693,762, the teachings of which are incorporated herein in their entirety). The choice of framework residues can

5 be critical in retaining high binding affinity. In principle, a framework sequence from any human antibody can serve as the template for CDR grafting; however, it has been demonstrated that straight CDR replacement into such a framework can lead to significant loss of binding affinity to the antigen (Tempest *et al., Biotechnology 9*: 266 (1992); Shalaby *et al., J. Exp. Med. 17*: 217 (1992)). The more homologous a human

10 antibody is to the original murine antibody, the less likely the human framework will introduce distortions into the mouse CDRs that could reduce affinity. Based on a sequence homology, I2R was selected to provide the framework for the humanized 3D1 heavy chain and H2F for the humanized 3D1 light chain variable region. Manheimer-Lory, A. *et al., J. Exp. Med.* 174(6):1639-52 (1991). Other highly homologous human

15 antibody chains would also be suitable to provide the humanized antibody framework, especially kappa light chains from human subgroup 4 and heavy chains from human subgroup 1 as defined by Kabat.

Normally the heavy chain and light chain from the same human antibody are chosen to provide the framework sequences, so as to reduce the possibility of

20 incompatibility in the assembling of the two chains. The I2R antibody shows a high homology to the 3D1 heavy and light chains and thus, was chosen to provide the framework for the initial humanized antibody model. The 3D1 light chain variable region, however, shows a significantly higher homology to the H2F framework compared to any others, including I2R. Therefore, H2F was chosen instead to provide

25 the framework for the humanized 3D1 light chain variable region, while I2R was selected to provide the framework for the heavy chain variable region.

The computer programs ABMOD and ENCODE (Levitt *et al.*, *J. Mol. Biol. 168:* 595 (1983)) were used to construct a molecular model of the 3D1 variable domain, which was used to locate the amino acids in the 3D1 framework that are close enough to the CDRs to potentially interact with them. To design the humanized 3D1 heavy and

5   light chain variable regions, the CDRs from the mouse 3D1 heavy chain were grafted into the framework regions of the human I2R heavy chain and the CDRs from the mouse 3D1 light chain grafted into the framework regions of the human H2F light chain. At framework positions where the computer model suggested significant contact with the CDRs, the amino acids from the mouse antibody were substituted for the

10   original human framework amino acids. For humanized 3D1, this was done at residues 27, 30, 48, 67, 68, 70 and 72 of the heavy chain and at residue 22 of the light chain. Furthermore, framework residues that occurred only rarely at their positions in the database of human antibodies were replaced by a human consensus amino acid at those positions. For humanized 3D1 this was done at residue 113 of the heavy chain and at

15   residue 3 of the light chain.

The sequence of the humanized 3D1 antibody heavy chain and light chain variable regions is shown in Figures 2A-2B. However, many of the potential CDR-contact residues are amenable to substitutions of other amino acids that may still allow the antibody to retain substantial affinity to the antigen. Table 1 lists a number of

20   positions in the framework where alternative amino acids may be suitable (LC = light chain, HU = heavy chain). The position specified in the table are the number of amino acids from the first amino acid of the mature chain, which is indicated by a double underline (Figures 2A-2B). For example, position LC-22 is the twenty second amino acid beginning from the doubled underlined Aspartic Acid, D, (or the forty second amino acid from the start codon).

25   amino acid from the start codon).

Table 1.   Complementarity Determining Region Amino Acids Substitutes and/or
Alternatives

Position	Humanized 3D1	Alternatives
LC-22	S	N
HU-27	Y	G
HU-30	T	S
HU-48	I	M
HU-67	K	R
HU-68	A	V
HU-70	M	I
HU-72	V	A

Likewise, many of the framework residues not in contact with the CDRs in the
humanized 3D1 heavy and light chains can accommodate substitutions of amino acids
from the corresponding positions of I2R and H2F frameworks, from other human
antibodies, from the mouse 3D1 antibody, or from other mouse antibodies, without
significant loss of the affinity or non-immunogenicity of the humanized antibody. Table
2 lists a number of additional positions in the framework where alternative amino acids
may be suitable.

Table 2.   Framework Region Amino Acid Substitutes and/or Alternatives

Position	Humanized 3D1	Alternatives
LC-3	V	Q
HU-113	T	I

Selection of various alternative amino acids may be used to produce versions of
humanized 3D1 that have varying combinations of affinity, specificity, non-

immunogenicity, ease of manufacture, and other desirable properties. Thus, the examples in the above tables are offered by way of illustration, not of limitation.

Example 3: Construction of Humanized 3D1:

Once the humanized variable region amino acid sequences had been designed, as

5   described above, genes were constructed to encode them, including signal peptides, splice donor signals and appropriate restriction sites (Figure 2A-2B). The light and heavy chain variable region genes were constructed and amplified using eight overlapping synthetic oligonucleotides ranging in length from approximately 65 to 80 bases (see He *et al. J. Immunol. 160*: 1029 (1998)). The oligos were annealed pairwise

10   and extended with the Klenow fragment of DNA polymerase I, yielding four double-stranded fragments. The resulting fragments were denatured, annealed, and extended with Klenow, yielding two fragments. These fragments were denatured, annealed pairwise, and extended once again, yielding a full-length gene. The resulting product was amplified by polymerase chain reaction (PCR) using Taq polymerase, gel-purified,

15   digested with XbaI, gel-purified again, and subcloned into the XbaI site of the pVk for the expression of light chain and pVg4 or pVg2.M3 for the expression of heavy chains. The pVk vector for kappa light chain expression has been previously described (See Co *et al., J. Immunol. 148*:1149 (1992)). The pVg4 vector for the gamma 4 heavy chain expression was constructed by replacing the XbaI - BamHI fragment of pVg1 containing

20   the g1 constant region gene (See Co *et al., J. Immunol. 148*: 1149 (1992)) with an approximately 2000 bp fragment of the human g4 constant region gene (Ellison and Hood, *Proc. Natl. Acad. Sci. USA* 79: 1984 (1982)) that extended from the HindIII site preceding the C_H1 exon of the g4 gene to 270 bp after the NsiI site following the C_H4 exon of the gene. The pVg2.M3 vector for the gamma 2 heavy chain expression was

25   described in Cole, *et al., J. Immunol. 159*: 3613 (1997). The pVg2.M3 is mutated from the human wildtype IgG2 by replacing the amino acids Val and Gly at positions 234 and

237 with Ala. This variant has a reduced interaction with its Fc receptors and thus has minimal antibody effector activity.

The structure of the final plasmids was verified by nucleotide sequencing and restriction mapping. All DNA manipulations were performed by standard methods well-known to those skilled in the art.

Two humanized 3D1, an IgG4 and an IgG2.M3, were generated for comparative studies. To construct a cell line producing humanized 3D1 (IgG4 or IgG2.M3), a light chain and the respective heavy chain plasmids were transfected into the mouse myeloma cell line Sp2/0-Ag14 (ATCC CRL 1581). Plasmids were also transfected into CHO cells using known methods in the art. Before transfection, the heavy and light chain-containing plasmids were linearized using restriction endonucleases. The kappa chain and the gamma2 chain were linearized using FspI; the gamma 4 chain was linearized using BstZ17I. Approximately 20 µg of the light chain and a heavy chain plasmid was transfected into 1×10^7 cells in PBS. Transfection was by electroporation using a Gene Pulser apparatus (BioRad) at 360 V and 25 µFD capacitance according to the manufacturer's instructions. The cells from each transfection were plated in four 96-well tissue culture plates, and after two days, selection medium (DMEM, 10% FCS, 1xHT supplement (Sigma), 0.25 mg/ml xanthine, 1 µg/ml mycophenolic acid) was applied.

After approximately two weeks, the clones that appeared were screened for antibody production by ELISA. Antibody from a high-producing clone was prepared by growing the cells to confluency in regular medium (DMEM with 10% FCS), then replacing the medium with a serum-free medium (Hybridoma SMF; Gibco) and culturing until maximum antibody titers were achieved in the culture. The culture supernatant was run through a protein A-Sepharose column (Pharmacia); antibody was eluted with 0.1 M Glycine, 100 mM NaCl, pH 3, neutralized and subsequently exchanged into phosphate-buffered saline (PBS). The purity of the antibody was verified by analyzing it on an acrylamide gel, and its concentration was determined by an OD_{280} reading, assuming 1.0 mg of antibody protein has an OD_{280} reading of 1.4.

Example 4: Affinity of Humanized Anti-B7-2 Antibody:

Competitive Binding Assay:

        The relative affinities, of the murine and humanized 3D1 antibodies for the B7-2 antigen were determined by competitive binding assays. Three-fold serial dilutions of

5   unlabelled humanized or murine 3D1 antibodies were mixed with a fixed amount of radio-iodinated murine 3D1 antibody (40,000-50,000 cpm per test in PBS containing 2% fetal calf serum).

        1×10^5 CHO cells expressing cell surface rhB7-2 (CHO/hB7-2) were added subsequently and the mixture (in a total volume of 200 ul) was incubated for 2 hr at 4° C

10   with gentle shaking. The cell-antibody suspension was then transferred to Sarstedt Micro Tubes (part #72.702) containing 100 ul 80% dibutyl phthalate-20% olive oil. After centrifugation in a microfuge, the Sarstedt tubes were plunged into dry ice for several minutes. Cell-bound ^{125}I was determined by clipping tips of each tube (containing cell pellets) into scintillation vials and counting in a gamma counter. Bound

15   and free counts were determined and the ratio plotted against the concentrations of the cold competitor antibodies according to the method of Berzofsky and Berkower (J. A. Berzofsky and I. J. Berkower, in Fundamental Immunology 9ed. W.E. Paul), Raven Press (New York), 595 (1984)).

Cell Line:

20   Recombinant Chinese Hamster Ovary (CHO) cell lines expressing hB7-2 on their membrane surfaces were cloned from cells transfected with B7-2 cDNA sequence and G418 resistance. Expression of hB7-2 on the CHO cell surface over many passages under selective pressure has been confirmed using murine anti-B7 antibodies and FACS analysis.

25   *Preparation of ^{125}I labeled anti-hB7 mAb and characterization:*

        Anti-hB7 antibodies were labeled with ^{125}I by reaction with ^{125}I-Bolton-Hunter reagent according to manufacturers instructions (Amersham Corp. Arlington Hts, IL). Protein was separated from free reagent with a NAP-25 column. An HPLC size-

exclusion column was used to confirm that the antibodies remained intact and were not aggregated, and to measure protein concentration against standards prepared from non-labeled antibody. Labeling typically resulted in 4 to 8 microcuries per microgram of protein, or approximately 30 to 60% of the antibody molecules labeled.

5   *Results:*

The competitive binding graph is shown in Figure 3. Each data point represents the average of triplicate determinations. Results showed that both humanized IgG4 and humanized IgG2.M3 anti-human B7-2 antibodies have a similar high binding affinity as the murine anti-human B7-2 antibody (approximately 1×10^9 M^{-1}), indicating no loss of

10   affinity for B7-2 in the humanization of 3D1. Both murine and humanized anti-B7-2 recognize cell surface expressed hB7-2 with high affinity.

Example 5.   Direct binding of Humanized Anti-B7 mAbs to CHO/hB7 Cells:

Cell binding assay:

Binding assays were begun by plating cells onto 96-well tissue culture plates at

15   10,000 CHO/hB7-2 cells per well. Two days later, adherent cells were gently washed with assay buffer containing nonfat dry milk protein (for blocking nonspecific binding) and sodium azide (to prevent internalization of antibodies by cells). For direct binding assays, ^{125}I-labeled anti-B7 antibodies (I^{125} -murine anti-human B7-2; 826 cpm/fmol; humanized anti-human B7-2, 883 cpm/fmol) were serially diluted in assay buffer and

20   incubated on cells overnight, allowing antibodies to bind to cell-surface B7 and come to equilibrium. Unbound antibody was gently washed from cells, and bound ^{125}I-labeled antibody was detected using an ^{125}I scintillant and photodetector system. Non-specific binding to CHO cells was determined for each dilution in the same manner, but on cells expressing the B7-1 molecule that is not recognized by the antibody being tested.

25   *Results:*

The direct binding graph is shown in Figure 4. The data, means of triplicate wells with nonspecific binding subtracted, were fit to a hyperbolic saturation curve using Graphpad PrismJ software. K_D of the antibodies determined as the concentration corresponding to half-maximal binding indicated that the murine and humanized anti-B7-2 mAbs had similar and high binding affinities ($\sim 10^{-9}$m) for B7-2. Both murine and humanized anti B7-2 antibodies recognize cell surface expressed hB7-2 with high affinity.

Example 6: Binding of Humanized Anti-B7 mAbs to Protein Ligands:

Affinity determination by BIACORE:

The BIACORE biosensor (BIACORE; Uppsalla, Sweden) was used to determine binding kinetics of murine and humanized anti-B7-2 human antibodies to human hB7-2Ig. HB7-2Ig was immobilized onto the dextran matrix of a BIACORE sensor chip. Humanized and murine anti-human B7-2 were tested at 200, 100, 50, and 20 nM. Each dilution was tested 4 times per run and a total of three separate runs performed. Anti-human B7-2 antibody binding was measured in real time by Surface Plasmon Resonance (SPR) and global analysis was performed using the bivalent binding model in BIA evaluation software (version 3.1). For each sample, the association (k_a), dissociation (k_d), and equilibrium dissociation constant (K_D) were determined.

Results:

Table 3 reports the mean values obtained for both murine and humanized anti-human B7-2 mAbs. The binding constants for the murine and humanized anti-B7-2 mAbs determined by SPR shows that the murine and humanized forms of the anti-B7-2 mAbs are similar and that the murine anti B7-2 mAb has a slightly higher binding constant for the immobilized hB7-2 Ig than does the humanized anti-B7-2. The approximately 2.8 fold higher affinity calculated for the murine anti-B7-2 mAb may represent a real, but slight difference between the murine and humanized anti B7-2 mAbs introduced during the humanization process. Another possibility may be due to

technical variation in the preparation, processing and analysis of these antibodies. As shown in Examples 4, 5, and 7, a difference was not observed in humanized hB7-2 binding affinity in cell based assays.

Table 3: Affinity of anti-B7 mAbs as determined by BIAcore

mAb	K_D Humanized	K_D Murine
Anti-B7-2	5.1×10^{-9} M	1.8×10^{-9} M

Preparation of hB7-2 Ig:

A soluble form of hB7-2Ig was recovered from culture medium of CHO cells engineered to secrete this protein. Recombinant hB7-2Ig was derived by fusing the DNA coding sequences corresponding to the extracellular domain of B7-2 gene to the hinge-CH2-CH3 domains of the human IgG1 heavy chain. Recombinant hB7-2Ig was purified from the culture medium by protein A.

Example 7. Inhibition of T cell costimulation by humanized anti-B7-2.

CD28⁺T cell/CHO-B7 proliferation assay

CD28$^+$ T cells, isolated as described herein, were washed once and resuspended in RPMI complete medium, supplemented with 2 ng/ml PMA (Calbiochem), to a cell density of 5×10^5 cells/ml. The CD28$^+$ T cells (100 ul, 5×10^4 cells) were added to the antibody/CHO/hB7-2 mixture (see below), incubated for 3 days at 37°C, 5% CO_2, and T cell proliferation was measured by pulsing for the last 6 hours of culture with 1 uCi of [³H]-thymidine (NEN, Boston, MA). The cells were harvested on a filter and the incorporated radioactivity was measured in a scintillation counter.

Materials:

CD28$^+$ T cells were isolated by negative selection with immunoabsorption from human peripheral blood lymphocytes, as described (June *et al.*, *Mol. Cell. Biol. 7*:4472-4481 (1987)). Buffy coats were obtained by leukophoresis of healthy human donors and

peripheral blood lymphocytes (PBL) were isolated by density gradient centrifugation. Monocytes were depleted from the PBL by plastic absorption. CD28$^+$ T cells were isolated from the non-adherent cells by negative selection using antibodies to CD11, CD20, CD16 and CD14, (this set of antibodies will coat all B cells, monocytes, large

5   granular lymphocytes, and CD28$^-$ T cells) and magnetic bead separation using goat anti-mouse immunoglobulin-coated magnetic particles.

CHO/hB7-2 cells were detached from the tissue culture plates by incubation in phosphate-buffered saline without Ca^{2+} and Mg^{2+} (PBS) with 0.5 mM EDTA and fixed with freshly prepared paraformaldehyde.

10   Various concentrations of anti-B7 antibody (in duplicate) were preincubated for 1 hour at 37°C, 5% CO$_2$ with 1x10^4 CHO/hB7-2 cells in 100 ul RPMI complete medium (RPMI 1640 medium, 10% fetal bovine serum (FBS),100 U/ml penicillin, 100 ug/ml streptomycin) in a microtiter plate (flat-bottom, 96-well, Costar, Cambridge, MA).

Results:

15   Figure 5 shows the results of the inhibition of human CD28$^+$T cell proliferation by the murine and humanized anti-hB7-2 mAbs. Both antibodies exhibit dose dependent inhibition of B7-2 driven T cell proliferation with similar IC$_{50}$ (Inhibitory concentration 50%; amount of antibody required to inhibit the maximal T cell proliferation by 50%) values of 72 pm (murine anti-hB7-2) and 50 pm (humanized anti-

20   hB7-2) indicating that both antibodies were similar and very effective in inhibiting the B7-2 T cell stimulatory signal. This demonstrates that the high affinity anti B7-2 mAbs can block B7-2 functionality by inhibiting (e.g., preventing) the activation and/or proliferation of human T cells. These mAbs are expected to exhibit similar capability in *in vivo* use to inhibit T cell response.

25   Example 8. Inhibition of mixed lymphocyte reactions by anti-B7-1 and anti-B7-2 mAbs

Mixed lymphocyte reactions (MLR): Normal peripheral blood lymphocytes (PBL) (responders) were cultured with irradiated (2,500 cGy) normal donor PBL

(stimulators) in RPMI 1640 containing 5% heat-inactivated human AB serum at 37°C in 5% CO2 at a final concentration of 10^6 cells/mL. Where indicated, murine anti-hB7-1 or murine anti-hB7-2 antibodies were added alone (10 ug/mL), in combination (10 ug/mL each), and in comparison with CTLA4Ig (10 or 20 ug/mL). Cells were cultured

5   in triplicate in microtiter plates in a final volume of 200 uL and proliferation was assessed by [^{3}H]-thymidine incorporation for the last 16 hours of culture. Secondary MLR was performed using the cells derived from the primary MLRs as responders. These cells were washed, cultured overnight, and restimulated as above using the same or different, third party stimulator PBLs. No inhibitors were added to the secondary

10   MLRs.

Results:

The determinations shown in Figure 6 were made by performing primary one-way MLRs in the absence or presence of B7 inhibitors (anti-B7, CTLA4Ig). The proliferation was measured after 3,4, or 5 days of culture.

15   In the primary MCR, the additional anti-B7-1 mAb alone had no inhibitory effect indicating a minor role for B7-1 alone in driving proliferation of responder T cells. Anti-B7-2 alone inhibited T cell proliferation on all days tested at a level comparable to hCTL4Ig, a recombinant protein known to bind to both B7-1 and B7-2. The combination of anti-B7-1 and anti-B7-2 was the most effective inhibitor of T cell

20   proliferation that completely inhibited this response on all days tested. The superior ability of the combined anti-B7-1 and anti-B7-2 to inhibit T cell proliferation, as compared to hCTL4Ig, reflects the higher affinity of the anti-B7 mAbs for B7-1 and B7-2 as compared to hCTL4Ig. The combined anti-B7-1 and anti-B7-2 mAbs were better inhibitors of T cell proliferation than anti-B7-2 alone, demonstrating the need to block

25   both stimulatory receptors to completely inhibit T cell responses. These results show that complete blockade of the B7-1 and B7-2 costimulators more completely abrogates alloresponsiveness in the MLR. Accordingly, these results indicate that methods of treatment including both anti B7-1 and anti B7-2 antibodies will be even more effective than either of the antibodies alone, especially where both costimulatory molecules are

functional. While the responder/stimulator pair, described herein, was not sensitive to inhibition by anti-B7-1 alone, some responder/stimulator pairs do exhibit moderate (0-50%) anti-B7-1 sensitivity.

To determine whether treatment with anti-B7 mAbs in the primary MLR had 5 resulted in the development of T cell hyporesponsiveness or anergy, the responder T cells from the primary MLRs were tested in secondary MLRs where the stimulators were either from the same donor as the primary MLR or from a third party. The results in Figure 7 show that the responder T cells from the primary MLR treated with anti-B7-2 alone failed to respond to the same stimulators as used in the primary MLR but 10 retained normal proliferative response to third party, unrelated stimulators indicating that these responder T cells were rendered tolerant to the original stimulator PBLs by treatment with anti-B7-2 and that the toleraization was specific for the stimulator antigens present in the primary MLR. With this responder/stimulator pair, treatment with anti-B7-2 alone resulted in tolerance to the stimulator cells; however, with other 15 responder/ stimulator pairs, the induction of tolerance may not be complete.

Figure 8 shows that the responder T cells from the primary MLR treated with anti-B7-1 and anti-B7-2 failed to respond to the same stimulators as used in the primary MLR, but retained normal proliferative response to third party, unrelated stimulators. This indicates that these responder T cells were rendered tolerant to the original 20 stimulator PBLs by treatment with the combined anti-B7-1 and anti-B7-2. The results obtained with this responder/stimulator pair are typical for other responder/stimulator pairs in that tolerance induction is the rule.

Example 9. Inhibition of Immune Responses in Non-Human Primates by Anti-B7 mAbs; Inhibition of Anti-Tetanus Responses.

25 *Method:*

Twelve tetanus naïve, 4-6 kg male cynomolgus macaques *(macaca fasicularis)* were divided into four experimental groups of three animal per group:

Group A; received 2 immunizations with 10 Lf Units (Flocculation Units) i.m. tetanus toxoid on day 0 and 42 (controls).

Group B; received 10 mg/kg of each humanized anti-B7.1 (1F1) and anti-B7.2 (3D1) i.v., at least 90 minutes before 10 Lf units i.m. tetanus toxoid on day 0; tetanus toxoid immunization only (without Ab pretreatment) on day 42 (Costimulation blockade with primary immunization).

Group C; received tetanus toxoid immunization only (without Ab pretreatment) on day 0; 10 mg/kg of each humanized anti-B7.1 and anti-B7.2 i.v., at least 90 minutes before 10 Lf units i.m. tetanus toxoid on day 42 (Costimulation blockade with secondary immunization).

Group D; received 10 mg/kg of each humanized anti-B7.1 (1F1) and anti-B7.2 (3D1) i.v., at least 90 minutes before 10 Lf units i.m. tetanus toxoid on day 0; received 10 mg/kg of each humanized anti-B7.1 and anti-B7.2 i.v., at least 90 minutes before 10 Lf units i.m. tetanus toxoid on day 42 (Costimulation blockade with primary and secondary immunization).

Serum samples for anti-tetanus antibody testing were collected on days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, and 84.

Anti-tetanus antibody ELISA:

96-well ELISA plates were coated with tetanus toxoid lot TP-1002 at 4 ug/ml. A four-log titration of serum samples was performed starting at 1:100. Ab binding to tetanus was detected with a combination of monoclonal anti-human IgG and polyclonal goat anti-rhesus IgM HRP-conjugated antibodies, and developed with TNB substrate.

Results:

Figure 9 shows the anti-tetanus IgM + IgG responses in monkeys immunized with tetanus toxoid and treated with the combined anti-B7-1 and anti-B7-2 mAbs.

Fourteen days after primary immunization, monkeys receiving tetanus toxoid

5   only (Group A) had developed serum anti-tetanus antibody titers of log 3 to 3.5 indicating a normal immune response to the tetanus antigen. An increase anti-tetanus response was seen after the second tetanus immunization on day 42. Monkeys treated with the combination of anti-B7.1 and anti-B7.2 before both the primary and secondary immunization (Group D) lacked detectable antibody titers until at least day 84.

10   Monkeys treated with anti-B7.1 and anti-B7.2 before the primary immunization only (Group B) maintained an undetectable anti-tetanus antibody titer until at least day 42, and a low (less than log 2.5) until at least day 84. Pretreatment with anti-B7.1 and anti-B7.2 before secondary tetanus immunization suppressed the secondary antibody response slightly (Group C vs. Group A). Therefore, the administration of anti-B7

15   antibodies concurrent with exposure to a new antigen (tetanus immunization) can prevent the development of a new antibody response and can lesson the strength of a secondary response to the same antigen. Since aspects of the rejection of transplanted organs and many autoimmune diseases involve the generation of antibody responses, treatment with humanized anti-B7 mAbs is useful in preventing organ rejection and in

20   treating autoimmune diseases.

Example 10: Serum half-life of anti-B7 antibodies in non-human primates.

The murine-anti-hB7-1 and murine-anti-hB7-2 mAbs were tested in non-human primates for serum half-life and target cell saturation. Three Cynomolgus monkeys were dosed with one dose each of a combination of the anti-hB7-1 and anti-hB7-2

25   mAbs at 2, 8, or 20 mg each mAb/kg body weight. The monkeys were analyzed for mAb binding to PBMC (Proliferative Blood Mononuclear Cells), serum mAb concentration, and primate anti-mouse antibody (PAMA) response (Table 6). PBMC saturation was determined by flow cytometry (FACS) where PBMCs isolated from the

blood of mAb dosed primates were stained with goat-anti-murine Ig-PE (% in vivo) or the PBMC were first reacted with the anti-hB7-1 and anti-hB7-2 mAbs followed by detection with the goat-anti-murine Ig-PE (% ex vivo). The level of PBMC saturation at the various time points was calculated by (% in vivo/% ex vivo) x 100. This study

5   shows that PBMC saturation for the anti-hB7-1 and anti-B7-2 mAbs falls below 80% between days 4 to 6 (mAbs @ 2mg/ks), days 6 to 8 (mAbs @ 8mg/kg), and days 13 to 20 (mAbs @ 20mg/kg) depending upon mAb dose. Although not measured directly, there was no apparent dramatic decrease in the numbers of circulating $B7^+$ cells.

      Serum half-lives of the anti-hB7-1 and anti-hB7-2 mAbs was measured with a

10   specific ELISA for each mAb using hB7-1Ig or hB7-2Ig as target and goat-anti-murine Ig HRP/ABTS for detection. These assays were sensitive to 400 ng/ml and 200 ng/ml for anti-hB7-2 and anti-hB7-1, respectively. PAMA responses were measured using a commercially available kit. The serum concentrations of the two anti-hB7 mAbs and the PAMA responses are shown at the individual dosage levels for each mAb. Both

15   mAbs exhibit similar serum half lines of ~48 hours as determined at all three dosage levels. Increasing mAb dosage increased serum mAb concentrations by a comparable factor at all dosages and times tested. When dosed at 20 mg/kg, circulating mAb levels of >30 ug/ml were found for each mAb at 6 days post dosing.

      PAMA responses to the anti-hB7-1 and anti-hB7-2 mAbs were low and were

20   first measurable beginning 10 days after serum mAb levels had fallen below 10 ug/ml.

      The serum half-life of humanized anti-human B7-2 was also determined in cynomolgus monkeys (n=6) dosed once with 10 mg/kg of humanized anti B7-2 antibody. Serum concentration was monitored by specific ELISA assay for each antibody using HRP-anti human IgG2 and ABTS.

25   Figure 10 shows the serum concentration of the humanized B7-2 mAb in cynomolgus monkeys during 42 days after dosing.

      The humanized anti-human B7-2 mAb exhibited an extended serum half-life in cynomolgus monkeys as compared to a value of approximately 2 days for the murine anti-human B7-2 mAb when dosed at the same level, demonstrating that the humanized

anti-human B7-2 mAb was retained in circulation much longer than the murine anti-B7-2 mAb.

Table 5. Results from the Preclinical primate studies

Time	Dose @ 2 mg each mAb/kg			Dose @ 8 mg each mAb/kg			Dose @ 20 mg each mAb/kg		
	Anti-hB7-2	PAMA	PBL Saturation	Anti-hB7-2	PAMA	PBL Saturation	Anti-hB7-2	PAMA	PBL Saturation
Hours (Days)	ug/mL	ng/mL	%	ug/mL	ng/mL	%	ug/mL	ng/mL	%
0	BQL	Neg.	0	BQL	Neg.	0	BQL	Neg.	0
.167	61			206			580		
.5	59		100	229		25	570		65
1	52			227			527		
3	52		100	230		100	548		100
5	50			139			464		
8	44			169			412		
24 (1D)	26		70	103		100	286		80
48 (2D)	15		100	59		100	196		100
96 (4D)	2.4		75	18		100	83		100
144 (6D)	BQL		95	3.9		100	32		100
192 (8D)	BQL		65	BQL		100	13		100
240 (10D)	BQL			BQL			3.9		
312 (13D)	BQL	Neg.	5	BQL	Neg.	55	BQL	Neg.	80
480 (20D)		2908	10		4080	10		517	20
684 (27D)		1260			1460			1094	
816 (34D)									

Example 11 Inhibition of Specific T-Cell Responses to Superantigens (Toxic shock

syndrome toxin-1; TSST-1)

NODscid mice were populated with human lymphocytes by the administration

of 10e8 human PBLs. After 28 days, the mice were treated with TSST-1 (10mg, I.P.)

5   with or without the treatment with the combined antibodies to human B7-1 and B7-2

(500 mg, I.V.). After 14 additional days, the presence of human lymphocytes, T-cells,

and TSST-1 specific T-cells (Vβ2-TCR-cells) in the peritoneal cavity was measured by

FACS using antibodies specific for human CD45, CD4, and human Vβ2-TCR.

Table 6

10

Addition		Human T-cells (%)	
TSST-1	Anti-B7-1 + anti-B7-2	Total	Vβ2$^+$
-	-	10.2	3.9
+	-	27.4	12.0
+	+	23.4	3.8

15   *Results:*

Table 6 shows the proportion of total human T cells and V$_\beta$2$^+$-TCR human T

cells (TSST-1 specific) found in the peritoneal cavity of hu-NODscid mice. Treatment

with TSST-1 greatly increased the percentage of human T cells and of TSST-1 specific

human T cells (V$_\beta$2$^+$) in the huNOD-scid mice. Treatment with the anti-human B7-1

20   and B7-2 mAbs moderately diminished the total human T cell response and completely

inhibited the expansion of the TSST-1 specific human T cells indicating that the anti-B-

7 mAbs could effectively inhibit human T cell superantigen mediated responses.

The teachings of all the references, patents and/or patent applications cited

herein are incorporated herein by reference in their entirety.

EQUIVALENTS

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.

-54-

CLAIMS

What is claimed is:

1. A method for transplanting cells to a patient in need thereof, comprising:

   a) obtaining cells from a donor,

5 b) contacting the cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2 and recipient cells from the patient for a period of time sufficient for tolerance induction, thereby obtaining a mixture, and

   c) introducing the mixture to the patient.

10 2. The method of Claim 1, wherein the cells from the donor are derived from bone marrow or blood.

3. The method of Claim 2, wherein the recipient cell is a lymphocyte.

4. The method of Claim 3, wherein the period of time is between about 12 hours and about 48 hours.

15 5. The method of Claim 4, wherein the period of time is about 36 hours.

6. The method of Claim 1, wherein the patient has a disease that is selected from the group consisting of: a proliferative disease, anemia and myeloid dysplasia syndrome.

7. The method of Claim 6, wherein the proliferative disease is selected from the group
20 consisting of: leukemia, lymphoma and cancer.

8.   The method of Claim 6, wherein the anemia is selected from the group consisting of: sickle-cell anemia, thalassemia and aplastic anemia.

9.   A method for transplanting cells to a patient in need thereof, comprising:
a)   obtaining cells from a donor,

5   b)   contacting the cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2, and tissue, organ or cells that express MHC Class I antigen, B7-1 and B7-2 molecules, for a period of time sufficient for tolerance induction, thereby obtaining a mixture, and

c)   introducing the mixture to the patient.

10   10.   The method of Claim 9, wherein the cells derived from the donor are derived from bone marrow, stem cells or immature blood cells.

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT THEREWITH

ABSTRACT OF THE DISCLOSURE

The invention relates to a humanized anti-B7-2 antibody that comprises a variable

5   region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

3D1 heavy chain variable region sequence

```
                                        30                                          60
ATG GGT TGG AAC TGT ATC ATC TTC TTT CTG GTT ACA ACA GCT ACA GGT GTG CAC TCC CAG
 M   G   W   N   C   I   I   F   F   L   V   T   T   A   T   G   V   H   S   Q

                                        90                                         120
GTC CAG CTG CAG CAG TCT GGG CCT GAG CTG GTG AGG CCT GGG GAA TCA GTG AAG ATT TCC
 V   Q   L   Q   Q   S   G   P   E   L   V   R   P   G   E   S   V   K   I   S

                                       150                                         180
TGC AAG GGT TCC GGC TAC ACA TTC ACT GAT TAT GCT ATA CAG TGG GTG AAG CAG AGT CAT
 C   K   G   S   G   Y   T   F   T   D   Y   A   I   Q   W   V   K   Q   S   H
                                        ─   ─   ─   ─   ─

                                       210                                         240
GCA AAG AGT CTA GAG TGG ATT GGA GTT ATT AAT ATT TAC TAT GAT AAT ACA AAC TAC AAC
 A   K   S   L   E   W   I   G   V   I   N   I   Y   Y   D   N   T   N   Y   N
                                     ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─

                                       270                                         300
CAG AAG TTT AAG GGC AAG GCC ACA ATG ACT GTA GAC AAA TCC TCC AGC ACA GCC TAT ATG
 Q   K   F   K   G   K   A   T   M   T   V   D   K   S   S   S   T   A   Y   M
 ─   ─   ─   ─   ─

                                       330                                         360
GAA CTT GCC AGA TTG ACA TCT GAG GAT TCT GCC ATC TAT TAC TGT GCA AGA GCG GCC TGG
 E   L   A   R   L   T   S   E   D   S   A   I   Y   Y   C   A   R   A   A   W
                                                                     ─   ─   ─

                                       390
TAT ATG GAC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TCA
 Y   M   D   Y   W   G   Q   G   T   S   V   T   V   S   S
 ─   ─   ─   ─
```

Figure 1 (A)

3D1 light chain variable region sequence

```
                                   30                                    60
ATG GAT TCA CAG GCC CAG GTT CTT ATA TTG CTG CTG CTA TGG GTA TCT GGT ACC TGT GGG
 M   D   S   Q   A   Q   V   L   I   L   L   L   L   W   V   S   G   T   C   G

                                   90                                   120
GAC ATT GTG CTG TCA CAG TCT CCA TCC TCC CTG GCT GTG TCA GCA GGA GAG AAG GTC ACT
 D   I   V   L   S   Q   S   P   S   S   L   A   V   S   A   G   E   K   V   T

                                  150                                   180
ATG AGC TGC AAA TCC AGT CAG AGT CTG CTC AAC AGT AGA ACC CGA GAG AAC TAC TTG GCT
 M   S   C   K   S   S   Q   S   L   L   N   S   R   T   R   E   N   Y   L   A

                                  210                                   240
TGG TAC CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATC TAC TGG GCA TCC ACT AGG
 W   Y   Q   Q   K   P   G   Q   S   P   K   L   L   I   Y   W   A   S   T   R

                                  270                                   300
GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC ACC
 E   S   G   V   P   D   R   F   T   G   S   G   S   G   T   D   F   T   L   T

                                  330                                   360
ATC AGC AGT GTG CAG GCT GAA GAC CTG GCA GTT TAT TAC TGC ACG CAA TCT TAT AAT CTT
 I   S   S   V   Q   A   E   D   L   A   V   Y   Y   C   T   Q   S   Y   N   L

                                  390
TAC ACG TTC GGA GGG GGG ACC AAG CTG GAA ATA AAA
 Y   T   F   G   G   G   T   K   L   E   I   K
```

Figure 1 (B)

Hu3D1 heavy chain variable region sequence

```
                                        30                                        60
ATG GGT TGG AAC TGT ATC ATC TTC TTT CTG GTT ACC ACA GCT ACA GGT GTG CAC TCC CAG
 M   G   W   N   C   I   I   F   F   L   V   T   T   A   T   G   V   H   S   Q

                                        90                                       120
GTC CAG CTG GTG CAG TCT GGG GCT GAG GTG AAG AAG CCT GGG AGC TCA GTG AAG GTG TCC
 V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   S   S   V   K   V   S

                                       150                                       180
TGC AAA GCT TCC GGC TAC ACA TTC ACT GAT TAT GCT ATA CAG TGG GTG AGA CAG GCT CCT
 C   K   A   S   G   Y   T   F   T   D   Y   A   I   Q   W   V   R   Q   A   P
                                        ‾   ‾   ‾   ‾   ‾

                                       210                                       240
-GGA CAG GGC CTC GAG TGG ATT GGA GTT ATT AAT ATT TAC TAT GAT AAT ACA AAC TAC AAC
 G   Q   G   L   E   W   I   G   V   I   N   I   Y   Y   D   N   T   N   Y   N
                                        ‾   ‾   ‾   ‾   ‾   ‾   ‾   ‾   ‾   ‾   ‾   ‾

                                       270                                       300
CAG AAG TTT AAG GGC AAG GCC ACA ATG ACT GTA GAC AAG TCG ACG AGC ACA GCC TAT ATG
 Q   K   F   K   G   K   A   T   M   T   V   D   K   S   T   S   T   A   Y   M
 ‾   ‾   ‾   ‾   ‾

                                       330                                       360
GAA CTT AGT TCT TTG AGA TCT GAG GAT ACG GCC GTT TAT TAC TGT GCA AGA GCG GCC TGG
 E   L   S   S   L   R   S   E   D   T   A   V   Y   Y   C   A   R   A   A   W
                                                                         ‾   ‾   ‾

                                       390
TAT ATG GAC TAC TGG GGT CAA GGT ACC CTT GTC ACC GTC TCC TCA
 Y   M   D   Y   W   G   Q   G   T   L   V   T   V   S   S
 ‾   ‾   ‾   ‾
```

Figure 2 (A)

Hu3D1 light chain variable region sequence

```
                                        30                                          60
ATG GAT TCA CAG GCC CAG GTT CTT ATA TTG CTG CTG CTA TGG GTA TCT GGC ACC TGT GGG
 M   D   S   Q   A   Q   V   L   I   L   L   L   L   W   V   S   G   T   C   G

                                        90                                         120
GAC ATT GTG CTG ACA CAG TCT CCA GAT TCC CTG GCT GTA AGC TTA GGA GAG AGG GCC ACT
 D   I   V   L   T   Q   S   P   D   S   L   A   V   S   L   G   E   R   A   T

                                       150                                         180
ATT AGC TGC AAA TCC AGT CAG AGT CTG CTC AAC AGT AGA ACC CGA GAG AAC TAC TTG GCT
 I   S   C   K   S   S   Q   S   L   L   N   S   R   T   R   E   N   Y   L   A

                                       210                                         240
TGG TAC CAG CAG AAA CCA GGG CAG CCT CCT AAA CTG CTG ATC TAC TGG GCA TCC ACT AGG
 W   Y   Q   Q   K   P   G   Q   P   P   K   L   L   I   Y   W   A   S   T   R

                                       270                                         300
GAA TCT GGG GTC CCT GAT CGC TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC ACC
 E   S   G   V   P   D   R   F   S   G   S   G   S   G   T   D   F   T   L   T

                                       330                                         360
ATC AGC AGT CTG CAG GCT GAA GAC GTG GCA GTT TAT TAC TGC ACG CAA TCT TAT AAT CTT
 I   S   S   L   Q   A   E   D   V   A   V   Y   Y   C   T   Q   S   Y   N   L

                                       390
TAC ACG TTC GGA CAG GGG ACC AAG GTG GAA ATA AAA
 Y   T   F   G   Q   G   T   K   V   E   I   K
```

Figure 2 (B)

Competition Binding Assay of Anti-B7.2 mAbs

Figure 3

Direct Binding Assay of Anti-B7.2 mAbs

■ Murine anti-human B7.2

▲ Humanized anti-human B7.2

Antibody bound (cpm)

Antibody Concentration (nM)

Figure 4

Inhibition of CD28$^+$ T Cell Proliferation by Anti-B7.2 mAbs

Figure 5

Inhibition of a Mixed Lymphocyte Reaction
by Anti-B7 Antibodies and CTLA4IG

Figure 6

Secondary MLR
Primary MLR Treated with Murine Anti-human B7.2

y-axis: [^{3}H]-Thymidine Incorporation (cpm)

x-axis: Time (Days)

Legend:
● Secondary MLR against primary stimulators
■ Secondary MLR against third party stimulators

Figure 7

Secondary MLR
Primary MLR Treated with
Murine Anti-human B7.1 + Murine Anti-human B7.2

Figure 8

Antibody Response to Tetanus Immunization During Costimulation Blockade with Humanized Anti-B7.1 and Anti-B7.2

Serum anti-tetanus IgG+IgM (log titer)

5.0 —
4.5 —
4.0 —
3.5 —
3.0 —
2.5 —
2.0 —
1.5 —

Tetanus: 0 7 14 21 28 35 42 49 56 63 70 77 84

time (days)

Group A (no anti-B7 mAbs)

Group B (10mg/kg anti-B7 mAbs Day 0)

Group C (10 mg/kg anti-B7 mAbs Day 42)

Group D (10 mg/kg anti-B7 mAbs Days 0 and 42)

Figure 9

Serum Concentration of Humanized Anti-B7-2 in cynomolgus Monkeys

Figure 10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE COPY FOR CONTINUING APPLICATION

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

____HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT____
____THEREWITH____

the specification of which (check one)

[ ]   is attached hereto.

[X]   was filed on _February 12, 1999__ as United States Application

     Number or PCT International Application No.____09/249,011____

     and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Not Claimed	Certified Copy Filed? YES	NO
(Number)	(Country)	(Day/Month/Year filed)	[ ]	[ ]	[ ]
(Number)	(Country)	(Day/Month/Year filed)	[ ]	[ ]	[ ]
(Number)	(Country)	(Day/Month/Year filed)	[ ]	[ ]	[ ]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the attorneys and/or agents associated with **Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02421-4799 Customer No. 21005,**

and _____,

to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please send correspondence to: [ ] Customer No. Noted Above
                                      or
                                      [X] **Address below:**

**David E. Brook
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
Two Militia Drive
Lexington, MA 02421-4799**

Direct telephone calls to: _David E. Brook_   Telephone No.: 781-861-6240

Direct facsimiles to: ____David E. Brook____   Facsimile No.: 781-861-9540

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

 or first inventor _____Man Sung Co_____

Inventor's Signature_____ Date _____

Residence _____10952 Wilkinson Avenue_____

_____Cupertino, California 95014_____

Citizenship _____U.S. Citizen_____

Post Office Address _____Same as above_____

Full name of second joint

inventor, if any _____ Maximiliano Vasquez _____

Inventor's Signature_____ Date _____

Residence _____ 3813 Louis Road _____

_____ Palo Alto, California 94303 _____

Citizenship _____ Costa Rica Citizen _____

Post Office Address ____ Same as above _____

Full name of third joint

inventor, if any _____ Beatriz Carreno _____

Inventor's Signature___ *Beatriz Carreno* _____ Date _6-10-99_

Residence _____ 37 Nash Road _____

_____ Acton, Massachusetts 01720 _____

Citizenship _____ Venezuela _____

Post Office Address _____ Same as above _____

Full name of fourth joint

inventor, if any _____ Abbie Cheryl Celniker _____

Inventor's Signature _*Abbie Celniker*_____ Date _6-4-99_

Residence _____ 560 Chestnut Street _____

_____ Newton, Massachusetts 02468 _____

Citizenship _____ U.S. Citizen _____

Post Office Address _____ Same as above _____

Full name of fifth joint

inventor, if any _____ Mary Collins _____

Inventor's Signature___ *Mary Collins* _____ Date _5/14/99_

Residence _____ 54 Rathbun Road _____

_____ Natick, Massachusetts 01760 _____

Citizenship _____ U.S. Citizen _____

Post Office Address _____ Same as above _____

Full name of sixth joint

   inventor, if any _____ Samuel Goldman

Inventor's Signature_____ _Samuel Goldman_____ Date _June 7, 1999_

Residence _____ 9 Mohawk Drive

   _____ Acton, Massachusetts 01720

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of seventh joint

   inventor, if any _____ Gary S. Gray

Inventor's Signature_____ _Gary S. Gray_____ Date _June 14, 1999_

Residence _____ 32 Milton Road

   _____ Brookline, Massachusetts 02145

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of eighth joint

   inventor, if any _____ Andrea Knight

Inventor's Signature_ _Andrea N. Knight_____ Date _June 7, 1999_

Residence _____ 35 Hampton Towne Estates

   _____ Hampton, New Hampshire 03842

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of ninth joint

   inventor, if any _____ Denise O'Hara

Inventor's Signature_____ _Denise O'Hara_____ Date _6/8/99_

Residence _____ 8 Jere Road

   _____ Reading, Massachusetts 01867

Citizenship _____ Great Britian

Post Office Address _____ Same as above

Full name of tenth joint

inventor, if any _____ Bonita Rup

Inventor's Signature_____ *Bonita* _____ Date 6/7/99

Residence _____ 234 Washington Street

_____ Reading, Massachusetts 01867

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of eleventh joint

inventor, if any _____ Geertruida M. Veldman

Inventor's Signature_____ _____ Date 6 - 10 - 99

Residence _____ 60 Woodmere Drive

_____ Sudbury, Massachusetts 01776

Citizenship _____ The Netherlands

Post Office Address _____ Same as above

K:\AGIUGLIA\GI\5315\PROS\Declaration

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

    I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

    HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT   THEREWITH

the specification of which (check one)

[ ]   is attached hereto.

[X]   was filed on _February 12, 1999_ as United States Application

    Number or PCT International Application No._____09/249,011_____

    and was amended on _____ (if applicable).

    I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

    I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

    I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Not Claimed	Certified Copy Filed? YES	NO
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ ]	[ ]	[ ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ ]	[ ]	[ ]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[ ]	[ ]	[ ]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____
(Application Number)   (Filing Date)

_____
(Application Number)   (Filing Date)

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the attorneys and/or agents associated with **Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02421-4799 Customer No. 21005,**

and _____ ,

to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please send correspondence to: [ ] Customer No. Noted Above
or
[X] **Address below:**

David E. Brook
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
Two Militia Drive
Lexington, MA 02421-4799

Direct telephone calls to: David E. Brook   Telephone No.: 781-861-6240

Direct facsimiles to: David E. Brook   Facsimile No.: 781-861-9540

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole
  or first inventor _____ Man Sung Co _____
Inventor's Signature_____ Date 5/20/99
Residence _____ 10952 Wilkinson Avenue _____
_____ Cupertino, California 95014 _____
Citizenship _____ U.S. Citizen _____
Post Office Address _____ Same as above _____

Full name of second joint

inventor, if any _____ Maximiliano Vasquez

Inventor's Signature _____ *[signature]* _____ Date __May 20, 1999__

Residence _____ 3813 Louis Road

_____ Palo Alto, California 94303

Citizenship _____ Costa Rica Citizen

Post Office Address _____ Same as above

Full name of third joint

inventor, if any _____ Beatriz Carreno

Inventor's Signature _____ Date _____

Residence _____ 37 Nash Road

_____ Acton, Massachusetts 01720

Citizenship _____ Venezuela

Post Office Address _____ Same as above

Full name of fourth joint

inventor, if any _____ Abbie Cheryl Celniker

Inventor's Signature _____ Date _____

Residence _____ 560 Chestnut Street

_____ Newton, Massachusetts 02468

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of fifth joint

inventor, if any _____ Mary Collins

Inventor's Signature _____ Date _____

Residence _____ 54 Rathbun Road

_____ Natick, Massachusetts 01760

Citizenship _____ U.S. Citizen

Post Office Address _____ Same as above

Full name of sixth joint

inventor, if any _____ Samuel Goldman _____

Inventor's Signature _____ Date _____

Residence _____ 9 Mohawk Drive _____

_____ Acton, Massachusetts 01720 _____

Citizenship _____ U.S. Citizen _____

Post Office Address _____ Same as above _____

Full name of seventh joint

inventor, if any _____ Gary S. Gray _____

Inventor's Signature _____ Date _____

Residence _____ 32 Milton Road _____

_____ Brookline, Massachusetts 02145 _____

Citizenship _____ U.S. Citizen _____

Post Office Address _____ Same as above _____

Full name of eighth joint

inventor, if any _____ Andrea Knight _____

Inventor's Signature _____ Date _____

Residence _____ 35 Hampton Towne Estates _____

_____ Hampton, New Hampshire 03842 _____

Citizenship _____ U.S. Citizen _____

Post Office Address _____ Same as above _____

Full name of ninth joint

inventor, if any _____ Denise O'Hara _____

Inventor's Signature _____ Date _____

Residence _____ 8 Jere Road _____

_____ Reading, Massachusetts 01867 _____

Citizenship _____ Great Britian _____

Post Office Address _____ Same as above _____

Full name of tenth joint

   inventor, if any _____ <u>Bonita Rup</u>_____

Inventor's Signature_____ Date _____

Residence _____ <u>234 Washington Street</u>_____

_____ <u>Reading, Massachusetts 01867</u>_____

Citizenship _____ <u>U.S. Citizen</u>_____

Post Office Address _____ <u>Same as above</u>_____

_____

Full name of eleventh joint

   inventor, if any _____ <u>Geertruida M. Veldman</u>_____

Inventor's Signature_____ Date _____

Residence _____ <u>60 Woodmere Drive</u>_____

_____ <u>Sudbury, Massachusetts 01776</u>_____

Citizenship _____ <u>The Netherlands</u>_____

Post Office Address _____ <u>Same as above</u>_____

_____

K:\AGIUGLIA\GI\5315\PROS\Declaration

SEQUENCE LISTING

<110> Co, Man Sung
        Vasquez, Maximiliano
        Carreno, Beatriz
        Celniker, Abbie Cheryl
        Collins, Mary
        Goldman, Samuel
        Gray, Gary S.
        Knight, Andrea
        O'Hara, Denise
        Rup, Bonita
        Veldman, Geertruida M.

<120> HUMANIZED IMMUNOGLOBULIN REACTIVE WITH
  B7-2 AND METHODS OF TREATMENT THEREWITH

<130> GI-5315

<140> 09/249,011
<141> 1999-02-12

<160> 20

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 405
<212> DNA
<213> Murine anti-B7-2 heavy chain

<220>
<221> CDS
<222> (1)...(405)
<223>

<400> 1
atg ggt tgg aac tgt atc atc ttc ttt ctg gtt aca aca gct aca ggt   48
Met Gly Trp Asn Cys Ile Ile Phe Phe Leu Val Thr Thr Ala Thr Gly
 1   5   10   15

gtg cac tcc cag gtc cag ctg cag cag tct ggg cct gag ctg gtg agg   96
Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg
            20   25   30

```
cct ggg gaa tca gtg aag att tcc tgc aag ggt tcc ggc tac aca ttc        144
Pro Gly Glu Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe
        35                  40                  45

act gat tat gct ata cag tgg gtg aag cag agt cat gca aag agt cta        192
Thr Asp Tyr Ala Ile Gln Trp Val Lys Gln Ser His Ala Lys Ser Leu
    50                  55                  60

gag tgg att gga gtt att aat att tac tat gat aat aca aac tac aac        240
Glu Trp Ile Gly Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn
65                  70                  75                  80

cag aag ttt aag ggc aag gcc aca atg act gta gac aaa tcc tcc agc        288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser
                85                  90                  95

aca gcc tat atg gaa ctt gcc aga ttg aca tct gag gat tct gcc atc        336
Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile
            100                 105                 110

tat tac tgt gca aga gcg gcc tgg tat atg gac tac tgg ggt caa gga        384
Tyr Tyr Cys Ala Arg Ala Ala Trp Tyr Met Asp Tyr Trp Gly Gln Gly
            115                 120                 125

acc tca gtc acc gtc tcc tca                                            405
Thr Ser Val Thr Val Ser Ser
    130                 135
```

```
        <210> 2
        <211> 135
        <212> PRT
        <213> Murine anti-B7-2 heavy chain

        <400> 2
Met Gly Trp Asn Cys Ile Ile Phe Phe Leu Val Thr Thr Ala Thr Gly
 1               5                   10                  15
Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg
            20                  25                  30
Pro Gly Glu Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe
        35                  40                  45
Thr Asp Tyr Ala Ile Gln Trp Val Lys Gln Ser His Ala Lys Ser Leu
    50                  55                  60
Glu Trp Ile Gly Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn
65                  70                  75                  80
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser
                85                  90                  95
Thr Ala Tyr Met Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile
            100                 105                 110
Tyr Tyr Cys Ala Arg Ala Ala Trp Tyr Met Asp Tyr Trp Gly Gln Gly
            115                 120                 125
Thr Ser Val Thr Val Ser Ser
    130                 135
```

<210> 3
<211> 396
<212> DNA
<213> Murine anti-B7-2 light chain

<220>
<221> CDS
<222> (1)...(396)

<400> 3

```
atg gat tca cag gcc cag gtt ctt ata ttg ctg ctg cta tgg gta tct        48
Met Asp Ser Gln Ala Gln Val Leu Ile Leu Leu Leu Leu Trp Val Ser
 1               5                  10                  15

ggt acc tgt ggg gac att gtg ctg tca cag tct cca tcc tcc ctg gct        96
Gly Thr Cys Gly Asp Ile Val Leu Ser Gln Ser Pro Ser Ser Leu Ala
                20                  25                  30

gtg tca gca gga gag aag gtc act atg agc tgc aaa tcc agt cag agt       144
Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser
            35                  40                  45

ctg ctc aac agt aga acc cga gag aac tac ttg gct tgg tac cag cag       192
Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu Ala Trp Tyr Gln Gln
        50                  55                  60

aaa cca ggg cag tct cct aaa ctg ctg atc tac tgg gca tcc act agg       240
Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
 65                  70                  75                  80

gaa tct ggg gtc cct gat cgc ttc aca ggc agt gga tct ggg aca gat       288
Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
                    85                  90                  95

ttc act ctc acc atc agc agt gtg cag gct gaa gac ctg gca gtt tat       336
Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr
                100                 105                 110

tac tgc acg caa tct tat aat ctt tac acg ttc gga ggg ggg acc aag       384
Tyr Cys Thr Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys
            115                 120                 125

ctg gaa ata aaa                                                        396
Leu Glu Ile Lys
    130
```

<210> 4
<211> 132
<212> PRT
<213> Murine anti-B7-2 light chain

<400> 4
```
Met Asp Ser Gln Ala Gln Val Leu Ile Leu Leu Leu Leu Trp Val Ser
1               5                   10                  15
Gly Thr Cys Gly Asp Ile Val Leu Ser Gln Ser Pro Ser Ser Leu Ala
            20                  25                  30
Val Ser Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser
        35                  40                  45
Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu Ala Trp Tyr Gln Gln
    50                  55                  60
Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65                  70                  75                  80
Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
                85                  90                  95
Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr
            100                 105                 110
Tyr Cys Thr Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys
        115                 120                 125
Leu Glu Ile Lys
    130
```

        <210> 5
        <211> 405
        <212> DNA
        <213> Humanized murine anti-human B7-2 heavy chain

        <220>
        <221> CDS
        <222> (1)...(405)

        <400> 5
```
atg ggt tgg aac tgt atc atc ttc ttt ctg gtt acc aca gct aca ggt        48
Met Gly Trp Asn Cys Ile Ile Phe Phe Leu Val Thr Thr Ala Thr Gly
1               5                   10                  15

gtg cac tcc cag gtc cag ctg gtg cag tct ggg gct gag gtg aag aag        96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
            20                  25                  30

cct ggg agc tca gtg aag gtg tcc tgc aaa gct tcc ggc tac aca ttc       144
Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
        35                  40                  45

act gat tat gct ata cag tgg gtg aga cag gct cct gga cag ggc ctc       192
Thr Asp Tyr Ala Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
        50                  55                  60

gag tgg att gga gtt att aat att tac tat gat aat aca aac tac aac       240
Glu Trp Ile Gly Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn
65                  70                  75                  80

cag aag ttt aag ggc aag gcc aca atg act gta gac aag tcg acg agc       288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
                85                  90                  95
```

```
aca gcc tat atg gaa ctt agt tct ttg aga tct gag gat acg gcc gtt        336
Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
        100             105             110

tat tac tgt gca aga gcg gcc tgg tat atg gac tac tgg ggt caa ggt        384
Tyr Tyr Cys Ala Arg Ala Ala Trp Tyr Met Asp Tyr Trp Gly Gln Gly
        115             120             125

acc ctt gtc acc gtc tcc tca                                            405
Thr Leu Val Thr Val Ser Ser
        130             135
```

```
        <210> 6
        <211> 135
        <212> PRT
        <213> Humanized murine anti-human B7-2 heavy chain


        <400> 6
Met Gly Trp Asn Cys Ile Ile Phe Phe Leu Val Thr Thr Ala Thr Gly
 1               5                  10                  15
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
                20                  25                  30
Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
        35                  40                  45
Thr Asp Tyr Ala Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
        50                  55                  60
Glu Trp Ile Gly Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn
65                  70                  75                  80
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
                85                  90                  95
Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
                100                 105                 110
Tyr Tyr Cys Ala Arg Ala Ala Trp Tyr Met Asp Tyr Trp Gly Gln Gly
        115                 120                 125
Thr Leu Val Thr Val Ser Ser
        130                 135
```

```
        <210> 7
        <211> 396
        <212> DNA
        <213> Humanized murine anti-human B7-2 light chain

        <220>
        <221> CDS
        <222> (1)...(396)

        <400> 7
atg gat tca cag gcc cag gtt ctt ata ttg ctg ctg cta tgg gta tct        48
Met Asp Ser Gln Ala Gln Val Leu Ile Leu Leu Leu Leu Trp Val Ser
 1               5                  10                  15
```

```
ggc acc tgt ggg gac att gtg ctg aca cag tct cca gat tcc ctg gct      96
Gly Thr Cys Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
            20                  25                  30

gta agc tta gga gag agg gcc act att agc tgc aaa tcc agt cag agt     144
Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser
            35                  40                  45

ctg ctc aac agt aga acc cga gag aac tac ttg gct tgg tac cag cag     192
Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu Ala Trp Tyr Gln Gln
            50                  55                  60

aaa cca ggg cag cct cct aaa ctg ctg atc tac tgg gca tcc act agg     240
Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65                  70                  75                  80

gaa tct ggg gtc cct gat cgc ttc agt ggc agt gga tct ggg aca gat     288
Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
                    85                  90                  95

ttc act ctc acc atc agc agt ctg cag gct gaa gac gtg gca gtt tat     336
Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
                100                 105                 110

tac tgc acg caa tct tat aat ctt tac acg ttc gga cag ggg acc aag     384
Tyr Cys Thr Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gln Gly Thr Lys
                115                 120                 125

gtg gaa ata aaa                                                      396
Val Glu Ile Lys
        130
```

```
<210> 8
<211> 132
<212> PRT
<213> Humanized murine anti-human B7-2 light chain

<400> 8
Met Asp Ser Gln Ala Gln Val Leu Ile Leu Leu Leu Leu Trp Val Ser
1               5                   10                  15
Gly Thr Cys Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala
            20                  25                  30
Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser
            35                  40                  45
Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu Ala Trp Tyr Gln Gln
        50                  55                  60
Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
65                  70                  75                  80
Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
                85                  90                  95
Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
                100                 105                 110
```

```
Tyr Cys Thr Gln Ser Tyr Asn Leu Tyr Thr Phe Gly Gln Gly Thr Lys
        115                 120                 125
Val Glu Ile Lys
    130
```

```
        <210> 9
        <211> 15
        <212> DNA
        <213> Artificial Sequence

        <220>
        <223> CDR1 of humanized murine anti-human B7-2 heavy
              chain

        <221> CDS
        <222> (1)...(15)

        <400> 9
gat tat gct ata cag                                              15
Asp Tyr Ala Ile Gln
 1               5

        <210> 10
        <211> 5
        <212> PRT
        <213> Artificial Sequence

        <220>
        <223> CDR1 of humanized murine anti-human B7-2 heavy
              chain

        <400> 10
Asp Tyr Ala Ile Gln
 1               5

        <210> 11
        <211> 51
        <212> DNA
        <213> Artificial Sequence

        <220>
        <223> CDR2 of humanized murine anti-human B7-2 heavy
              chain

        <221> CDS
        <222> (1)...(51)

        <400> 11
gtt att aat att tac tat gat aat aca aac tac aac cag aag ttt aag   48
Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn Gln Lys Phe Lys
 1               5                   10                  15

ggc                                                              51
Gly
```

```
<210> 12
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2 of humanized murine anti-human B7-2 heavy
      chain

<400> 12
Val Ile Asn Ile Tyr Tyr Asp Asn Thr Asn Tyr Asn Gln Lys Phe Lys
 1               5                   10                  15
Gly


<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR3 of humanized murine anti-human B7-2 heavy
      chain

<221> CDS
<222> (1)...(21)

<400> 13
gcg gcc tgg tat atg gac tac                                    21
Ala Ala Trp Tyr Met Asp Tyr
 1               5


<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3 of humanized murine anti-human B7-2 heavy
      chain

<400> 14
Ala Ala Trp Tyr Met Asp Tyr
 1               5


<210> 15
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR1 of humanized murine anti-human B7-2 light
      chain
```

```
<221> CDS
<222> (1)...(51)

<400> 15
aaa tcc agt cag agt ctg ctc aac agt aga acc cga gag aac tac ttg      48
Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu
 1               5                   10                  15

gct                                                                  51
Ala
```

```
<210> 16
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 of humanized murine anti-human B7-2 light
      chain

<400> 16
Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Glu Asn Tyr Leu
 1               5                   10                  15
Ala
```

```
<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR2 of humanized murine anti-human B7-2 light
      chain

<221> CDS
<222> (1)...(21)

<400> 17
tgg gca tcc act agg gaa tct                                         21
Trp Ala Ser Thr Arg Glu Ser
 1               5
```

```
<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2 of humanized murine anti-human B7-2 light
      chain
```

```
     <400> 18
Trp Ala Ser Thr Arg Glu Ser
 1               5


     <210> 19
     <211> 24
     <212> DNA
     <213> Artificial Sequence


     <220>
     <223> CDR3 of humanized murine anti-human B7-2 light
           chain


     <221> CDS
     <222> (1)...(24)


     <400> 19
acg caa tct tat aat ctt tac acg                                24
Thr Gln Ser Tyr Asn Leu Tyr Thr
 1               5



     <210> 20
     <211> 8
     <212> PRT
     <213> Artificial Sequence


     <220>
     <223> CDR3 of humanized murine anti-human B7-2 light
           chain


     <400> 20
Thr Gln Ser Tyr Asn Leu Tyr Thr
 1               5
```